Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12433210,plasma steady-state concentration,"During hypoxemia, MCP plasma steady-state concentration increased significantly from 50.72 +/- 1.06 to 63.62 +/- 1.79 ng/mL, and later decreased to 55.83 +/- 1.15 ng/mL during the post-hypoxemic recovery period.",Effects of acute moderate hypoxemia on kinetics of metoclopramide and its metabolites in chronically instrumented sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433210/),[ng] / [ml],50.72,1274,DB01233,Metoclopramide
,12433210,plasma steady-state concentration,"During hypoxemia, MCP plasma steady-state concentration increased significantly from 50.72 +/- 1.06 to 63.62 +/- 1.79 ng/mL, and later decreased to 55.83 +/- 1.15 ng/mL during the post-hypoxemic recovery period.",Effects of acute moderate hypoxemia on kinetics of metoclopramide and its metabolites in chronically instrumented sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433210/),[ng] / [ml],63.62,1275,DB01233,Metoclopramide
,12433210,plasma steady-state concentration,"During hypoxemia, MCP plasma steady-state concentration increased significantly from 50.72 +/- 1.06 to 63.62 +/- 1.79 ng/mL, and later decreased to 55.83 +/- 1.15 ng/mL during the post-hypoxemic recovery period.",Effects of acute moderate hypoxemia on kinetics of metoclopramide and its metabolites in chronically instrumented sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433210/),[ng] / [ml],55.83,1276,DB01233,Metoclopramide
,12433210,Total body clearance (CL(TB)),"Total body clearance (CL(TB)) of MCP was significantly decreased from 274.2 +/- 48.0 L/h to 205.40 +/- 28.2 L/h during hypoxemia, and later restored to 245.8 +/- 44.2 L/h during the post-hypoxemic period.",Effects of acute moderate hypoxemia on kinetics of metoclopramide and its metabolites in chronically instrumented sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433210/),[l] / [h],274.2,1277,DB01233,Metoclopramide
,12433210,Total body clearance (CL(TB)),"Total body clearance (CL(TB)) of MCP was significantly decreased from 274.2 +/- 48.0 L/h to 205.40 +/- 28.2 L/h during hypoxemia, and later restored to 245.8 +/- 44.2 L/h during the post-hypoxemic period.",Effects of acute moderate hypoxemia on kinetics of metoclopramide and its metabolites in chronically instrumented sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433210/),[l] / [h],205.40,1278,DB01233,Metoclopramide
,12433210,Total body clearance (CL(TB)),"Total body clearance (CL(TB)) of MCP was significantly decreased from 274.2 +/- 48.0 L/h to 205.40 +/- 28.2 L/h during hypoxemia, and later restored to 245.8 +/- 44.2 L/h during the post-hypoxemic period.",Effects of acute moderate hypoxemia on kinetics of metoclopramide and its metabolites in chronically instrumented sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433210/),[l] / [h],245.8,1279,DB01233,Metoclopramide
,9267751,Time,"Time and peak value of maximum plasma 8-MOP concentrations (Tmax, Cmax) ranged from 1 to 3 h and from 124 to 540 ng/ml, respectively.",Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267751/),h,1 to 3,6618,DB01233,Metoclopramide
,9267751,"peak value of maximum plasma 8-MOP concentrations (Tmax, Cmax)","Time and peak value of maximum plasma 8-MOP concentrations (Tmax, Cmax) ranged from 1 to 3 h and from 124 to 540 ng/ml, respectively.",Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267751/),[ng] / [ml],124 to 540,6619,DB01233,Metoclopramide
,9267751,area under the curve,"Individual values of the area under the curve of time-related 8-MOP concentration were between 284 and 1,158 ng-h/ml.",Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267751/),[ng-h] / [ml],"284 and 1,158",6620,DB01233,Metoclopramide
,2590616,maximum plasma concentration,"After intranasal administration of metoclopramide, (5 mg in 0.5 ml sterile water) the maximum plasma concentration of 13.5 +/- 7.3 (mean +/- s.d.) ng ml-1 was achieved.",Bioavailability of intranasal metoclopramide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590616/),[ng] / [ml],13.5,8839,DB01233,Metoclopramide
,2590616,Absolute bioavailability,"Absolute bioavailability was 50.5 +/- 29.5%, 110 +/- 41 min later.",Bioavailability of intranasal metoclopramide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590616/),%,50.5,8840,DB01233,Metoclopramide
,2590616,Absolute bioavailability,"Absolute bioavailability was 50.5 +/- 29.5%, 110 +/- 41 min later.",Bioavailability of intranasal metoclopramide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590616/),min,110,8841,DB01233,Metoclopramide
,3780825,terminal half-life,The terminal half-life of metoclopramide was 7.1 +/- 0.4 h (mean +/- SEM) and was not affected by the route of drug administration.,Oral bioavailability of high-dose metoclopramide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780825/),h,7.1,11046,DB01233,Metoclopramide
,3780825,bioavailability,Mean bioavailability was 86.6 +/- 4.7% and the range (65-118%) was less than that reported for standard doses.,Oral bioavailability of high-dose metoclopramide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780825/),%,86.6,11047,DB01233,Metoclopramide
,7286040,neutralising capacity,"In 8 healthy subjects the absorption of cimetidine was investigated when given alone, together with 60 ml aluminium/magnesium hydroxide containing antacid (neutralising capacity 26 mmol HCl/10 ml), and together with liquid metoclopramide 14 mg.",Impaired cimetidine absorption due to antacids and metoclopramide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286040/),[hcl·mM] / [10·ml],26,11176,DB01233,Metoclopramide
,3411454,terminal elimination half-lives,"The terminal elimination half-lives in maternal and fetal plasma averaged 71.3 and 86.8 min, respectively, with fetal half-life being significantly longer.",Metoclopramide pharmacokinetics in pregnant and nonpregnant sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411454/),min,71.3,11520,DB01233,Metoclopramide
,3411454,terminal elimination half-lives,"The terminal elimination half-lives in maternal and fetal plasma averaged 71.3 and 86.8 min, respectively, with fetal half-life being significantly longer.",Metoclopramide pharmacokinetics in pregnant and nonpregnant sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411454/),min,86.8,11521,DB01233,Metoclopramide
,3411454,Total body clearance,"Total body clearance and volume of distribution averaged 3.5 L/h/kg and 5.8 L/kg, respectively, in the pregnant ewe, and 4.5 L/h/kg and 6.9 L/kg, respectively, in the nonpregnant animals.",Metoclopramide pharmacokinetics in pregnant and nonpregnant sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411454/),[l] / [h·kg],3.5,11522,DB01233,Metoclopramide
,3411454,Total body clearance,"Total body clearance and volume of distribution averaged 3.5 L/h/kg and 5.8 L/kg, respectively, in the pregnant ewe, and 4.5 L/h/kg and 6.9 L/kg, respectively, in the nonpregnant animals.",Metoclopramide pharmacokinetics in pregnant and nonpregnant sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411454/),[l] / [h·kg],4.5,11523,DB01233,Metoclopramide
,3411454,volume of distribution,"Total body clearance and volume of distribution averaged 3.5 L/h/kg and 5.8 L/kg, respectively, in the pregnant ewe, and 4.5 L/h/kg and 6.9 L/kg, respectively, in the nonpregnant animals.",Metoclopramide pharmacokinetics in pregnant and nonpregnant sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411454/),[l] / [kg],5.8,11524,DB01233,Metoclopramide
,3411454,volume of distribution,"Total body clearance and volume of distribution averaged 3.5 L/h/kg and 5.8 L/kg, respectively, in the pregnant ewe, and 4.5 L/h/kg and 6.9 L/kg, respectively, in the nonpregnant animals.",Metoclopramide pharmacokinetics in pregnant and nonpregnant sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411454/),[l] / [kg],6.9,11525,DB01233,Metoclopramide
,3411454,terminal elimination half-life,The terminal elimination half-life in the nonpregnant ewes averaged 67.5 min.,Metoclopramide pharmacokinetics in pregnant and nonpregnant sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411454/),min,67.5,11526,DB01233,Metoclopramide
,3547879,maximum blood concentration,"Coadministration of cyclosporine with metoclopramide resulted in a significant increase in mean maximum blood concentration (567 ng/mL nu 388 ng/mL) and mean area under the blood concentration nu time curve (4120 ng X h/mL nu 3370 ng X h/mL), and a significant decrease in mean time to reach maximum concentration: The mean increase in area under the blood concentration versus time curve was 29%.",The effect of oral metoclopramide on the absorption of cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3547879/),[ng] / [ml],567,12990,DB01233,Metoclopramide
,3547879,area under the blood concentration nu time curve,"Coadministration of cyclosporine with metoclopramide resulted in a significant increase in mean maximum blood concentration (567 ng/mL nu 388 ng/mL) and mean area under the blood concentration nu time curve (4120 ng X h/mL nu 3370 ng X h/mL), and a significant decrease in mean time to reach maximum concentration: The mean increase in area under the blood concentration versus time curve was 29%.",The effect of oral metoclopramide on the absorption of cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3547879/),[h·ng] / [ml],4120,12991,DB01233,Metoclopramide
>,10708180,gastric residual volumes,"Ten adult, critically ill, mechanically ventilated patients not tolerating a fiber-containing EN product defined as a single aspirated gastric residual volume >150 mL or two aspirated gastric residual volumes >120 mL during a 12-hr period.","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),,120,15818,DB01233,Metoclopramide
,10708180,mean residence time of absorption,"Metoclopramide and cisapride had a significantly shorter mean residence time of absorption than erythromycin (6.3+/-4.5 [SEM] mins and 10.9+/-5.8 vs. 30.1+/-4.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,6.3,15819,DB01233,Metoclopramide
,10708180,mean residence time of absorption,"Metoclopramide and cisapride had a significantly shorter mean residence time of absorption than erythromycin (6.3+/-4.5 [SEM] mins and 10.9+/-5.8 vs. 30.1+/-4.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,10.9,15820,DB01233,Metoclopramide
,10708180,mean residence time of absorption,"Metoclopramide and cisapride had a significantly shorter mean residence time of absorption than erythromycin (6.3+/-4.5 [SEM] mins and 10.9+/-5.8 vs. 30.1+/-4.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,30.1,15821,DB01233,Metoclopramide
,10708180,time to peak concentration,"Metoclopramide (9.7+/-15.3 mins) had a significantly shorter time to peak concentration compared with erythromycin and placebo (60.7+/-8.1 and 50.9+/-13.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,9.7,15822,DB01233,Metoclopramide
,10708180,time to peak concentration,"Metoclopramide (9.7+/-15.3 mins) had a significantly shorter time to peak concentration compared with erythromycin and placebo (60.7+/-8.1 and 50.9+/-13.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,60.7,15823,DB01233,Metoclopramide
,10708180,time to peak concentration,"Metoclopramide (9.7+/-15.3 mins) had a significantly shorter time to peak concentration compared with erythromycin and placebo (60.7+/-8.1 and 50.9+/-13.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,50.9,15824,DB01233,Metoclopramide
,10708180,time to onset of absorption,The time to onset of absorption was significantly shorter for metoclopramide vs. cisapride (5.7+/-4.5 vs. 22.9+/-5.7 mins [p<.05]).,"Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,5.7,15825,DB01233,Metoclopramide
,10708180,time to onset of absorption,The time to onset of absorption was significantly shorter for metoclopramide vs. cisapride (5.7+/-4.5 vs. 22.9+/-5.7 mins [p<.05]).,"Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,22.9,15826,DB01233,Metoclopramide
,3780824,biological half-life,"The biological half-life of metoclopramide was 9.9 h, the volume of distribution was 9.9 l/kg and the clearance was 0.68 l/h/kg.",Antiemetic effect and pharmacokinetics of high dose metoclopramide in cancer patients treated with cisplatin-containing chemotherapy regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780824/),h,9.9,17589,DB01233,Metoclopramide
,3780824,volume of distribution,"The biological half-life of metoclopramide was 9.9 h, the volume of distribution was 9.9 l/kg and the clearance was 0.68 l/h/kg.",Antiemetic effect and pharmacokinetics of high dose metoclopramide in cancer patients treated with cisplatin-containing chemotherapy regimens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780824/),[l] / [kg],9.9,17590,DB01233,Metoclopramide
,3780824,clearance,"The biological half-life of metoclopramide was 9.9 h, the volume of distribution was 9.9 l/kg and the clearance was 0.68 l/h/kg.",Antiemetic effect and pharmacokinetics of high dose metoclopramide in cancer patients treated with cisplatin-containing chemotherapy regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780824/),[l] / [h·kg],0.68,17591,DB01233,Metoclopramide
,3199269,serum concentrations,Metoclopramide serum concentrations (mean +/- SD) ranged from 56.2 +/- 23.5 to 32.7 +/- 13.2 ng/ml within a 6-h dosing interval at steady state.,Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199269/),[ng] / [ml],56.2,21164,DB01233,Metoclopramide
,3199269,serum concentrations,Metoclopramide serum concentrations (mean +/- SD) ranged from 56.2 +/- 23.5 to 32.7 +/- 13.2 ng/ml within a 6-h dosing interval at steady state.,Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199269/),[ng] / [ml],32.7,21165,DB01233,Metoclopramide
,3199269,Tmax,"There were no significant differences between the first versus tenth dose values for Tmax (2.0 +/- 0.5 versus 2.2 +/- 0.4 h), Kel (0.14 +/- 0.03 versus 0.17 +/- 0.04 h-1), Vdarea (4.9 +/- 0.4 versus 4.4 +/- 0.6 L/kg), or clearance (0.66 +/- 0.16 versus 0.67 +/- 0.13 L/h/kg).",Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199269/),h,2.0,21166,DB01233,Metoclopramide
,3199269,Tmax,"There were no significant differences between the first versus tenth dose values for Tmax (2.0 +/- 0.5 versus 2.2 +/- 0.4 h), Kel (0.14 +/- 0.03 versus 0.17 +/- 0.04 h-1), Vdarea (4.9 +/- 0.4 versus 4.4 +/- 0.6 L/kg), or clearance (0.66 +/- 0.16 versus 0.67 +/- 0.13 L/h/kg).",Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199269/),h,2.2,21167,DB01233,Metoclopramide
,3199269,Kel,"There were no significant differences between the first versus tenth dose values for Tmax (2.0 +/- 0.5 versus 2.2 +/- 0.4 h), Kel (0.14 +/- 0.03 versus 0.17 +/- 0.04 h-1), Vdarea (4.9 +/- 0.4 versus 4.4 +/- 0.6 L/kg), or clearance (0.66 +/- 0.16 versus 0.67 +/- 0.13 L/h/kg).",Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199269/),1/[h],0.14,21168,DB01233,Metoclopramide
,3199269,Kel,"There were no significant differences between the first versus tenth dose values for Tmax (2.0 +/- 0.5 versus 2.2 +/- 0.4 h), Kel (0.14 +/- 0.03 versus 0.17 +/- 0.04 h-1), Vdarea (4.9 +/- 0.4 versus 4.4 +/- 0.6 L/kg), or clearance (0.66 +/- 0.16 versus 0.67 +/- 0.13 L/h/kg).",Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199269/),1/[h],0.17,21169,DB01233,Metoclopramide
,3199269,Vdarea,"There were no significant differences between the first versus tenth dose values for Tmax (2.0 +/- 0.5 versus 2.2 +/- 0.4 h), Kel (0.14 +/- 0.03 versus 0.17 +/- 0.04 h-1), Vdarea (4.9 +/- 0.4 versus 4.4 +/- 0.6 L/kg), or clearance (0.66 +/- 0.16 versus 0.67 +/- 0.13 L/h/kg).",Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199269/),[l] / [kg],4.9,21170,DB01233,Metoclopramide
,3199269,Vdarea,"There were no significant differences between the first versus tenth dose values for Tmax (2.0 +/- 0.5 versus 2.2 +/- 0.4 h), Kel (0.14 +/- 0.03 versus 0.17 +/- 0.04 h-1), Vdarea (4.9 +/- 0.4 versus 4.4 +/- 0.6 L/kg), or clearance (0.66 +/- 0.16 versus 0.67 +/- 0.13 L/h/kg).",Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199269/),[l] / [kg],4.4,21171,DB01233,Metoclopramide
,3199269,clearance,"There were no significant differences between the first versus tenth dose values for Tmax (2.0 +/- 0.5 versus 2.2 +/- 0.4 h), Kel (0.14 +/- 0.03 versus 0.17 +/- 0.04 h-1), Vdarea (4.9 +/- 0.4 versus 4.4 +/- 0.6 L/kg), or clearance (0.66 +/- 0.16 versus 0.67 +/- 0.13 L/h/kg).",Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199269/),[l] / [h·kg],0.66,21172,DB01233,Metoclopramide
,3199269,clearance,"There were no significant differences between the first versus tenth dose values for Tmax (2.0 +/- 0.5 versus 2.2 +/- 0.4 h), Kel (0.14 +/- 0.03 versus 0.17 +/- 0.04 h-1), Vdarea (4.9 +/- 0.4 versus 4.4 +/- 0.6 L/kg), or clearance (0.66 +/- 0.16 versus 0.67 +/- 0.13 L/h/kg).",Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199269/),[l] / [h·kg],0.67,21173,DB01233,Metoclopramide
,3199269,t 1/2,"The youngest subject (3.5 weeks) had a metoclopramide t 1/2 of 23.1 h following initial dose, which decreased to 10.3 h at steady-state.",Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199269/),h,23.1,21174,DB01233,Metoclopramide
,3199269,t 1/2,"The youngest subject (3.5 weeks) had a metoclopramide t 1/2 of 23.1 h following initial dose, which decreased to 10.3 h at steady-state.",Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199269/),h,10.3,21175,DB01233,Metoclopramide
,6115902,apparent volume of distribution,"After intravenous, intramuscular and oral administration of clebopride in the rat and the dog its apparent volume of distribution is high (1.6-3.2 1 kg-1) and it has a longer biological half-life than metoclopramide in both species.","The pharmacokinetics of a new benzamide drug clebopride, in the rat and the dog. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115902/),[1] / [kg],1.6-3.2,21221,DB01233,Metoclopramide
,7866522,Absolute recoveries,"Absolute recoveries in plasma ranged from 76.5-94.7%, 79.2-96.8%, 80.3-102.2% for MCP, mdMCP and ddMCP, respectively.",Determination of metoclopramide and two of its metabolites using a sensitive and selective gas chromatographic-mass spectrometric assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7866522/),%,76.5-94.7,21763,DB01233,Metoclopramide
,7866522,Absolute recoveries,"Absolute recoveries in plasma ranged from 76.5-94.7%, 79.2-96.8%, 80.3-102.2% for MCP, mdMCP and ddMCP, respectively.",Determination of metoclopramide and two of its metabolites using a sensitive and selective gas chromatographic-mass spectrometric assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7866522/),%,79.2-96.8,21764,DB01233,Metoclopramide
,7866522,Absolute recoveries,"Absolute recoveries in plasma ranged from 76.5-94.7%, 79.2-96.8%, 80.3-102.2% for MCP, mdMCP and ddMCP, respectively.",Determination of metoclopramide and two of its metabolites using a sensitive and selective gas chromatographic-mass spectrometric assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7866522/),%,80.3-102.2,21765,DB01233,Metoclopramide
,7866522,recoveries,"In urine, recoveries ranged from 56.5-87.8%, 61.5-87.5%, 62.6-90.2% for MCP, mdMCP and ddMCP, respectively.",Determination of metoclopramide and two of its metabolites using a sensitive and selective gas chromatographic-mass spectrometric assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7866522/),%,56.5-87.8,21766,DB01233,Metoclopramide
,7866522,recoveries,"In urine, recoveries ranged from 56.5-87.8%, 61.5-87.5%, 62.6-90.2% for MCP, mdMCP and ddMCP, respectively.",Determination of metoclopramide and two of its metabolites using a sensitive and selective gas chromatographic-mass spectrometric assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7866522/),%,61.5-87.5,21767,DB01233,Metoclopramide
,7866522,recoveries,"In urine, recoveries ranged from 56.5-87.8%, 61.5-87.5%, 62.6-90.2% for MCP, mdMCP and ddMCP, respectively.",Determination of metoclopramide and two of its metabolites using a sensitive and selective gas chromatographic-mass spectrometric assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7866522/),%,62.6-90.2,21768,DB01233,Metoclopramide
,7866522,Recoveries,"Recoveries in bile ranged from 83.5-100.9%, 78.5-90.5%, 66.9-79.2% for MCP, mdMCP and ddMCP, respectively.",Determination of metoclopramide and two of its metabolites using a sensitive and selective gas chromatographic-mass spectrometric assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7866522/),%,83.5-100.9,21769,DB01233,Metoclopramide
,7866522,Recoveries,"Recoveries in bile ranged from 83.5-100.9%, 78.5-90.5%, 66.9-79.2% for MCP, mdMCP and ddMCP, respectively.",Determination of metoclopramide and two of its metabolites using a sensitive and selective gas chromatographic-mass spectrometric assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7866522/),%,78.5-90.5,21770,DB01233,Metoclopramide
,7866522,Recoveries,"Recoveries in bile ranged from 83.5-100.9%, 78.5-90.5%, 66.9-79.2% for MCP, mdMCP and ddMCP, respectively.",Determination of metoclopramide and two of its metabolites using a sensitive and selective gas chromatographic-mass spectrometric assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7866522/),%,66.9-79.2,21771,DB01233,Metoclopramide
,8112369,apparent oral clearance,The pharmacokinetic values in patients with cholestasis (median apparent oral clearance 0.5 l.kg-1.h-1; median t1/2 4.5 h) were similar to those previously reported in patients with healthy liver function.,Minimal biliary excretion and enterohepatic recirculation of metoclopramide in patients with extrahepatic cholestasis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112369/),[l] / [h·kg],0.5,34345,DB01233,Metoclopramide
,8112369,t1/2,The pharmacokinetic values in patients with cholestasis (median apparent oral clearance 0.5 l.kg-1.h-1; median t1/2 4.5 h) were similar to those previously reported in patients with healthy liver function.,Minimal biliary excretion and enterohepatic recirculation of metoclopramide in patients with extrahepatic cholestasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112369/),h,4.5,34346,DB01233,Metoclopramide
,18165446,Cmax,"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],14.12,37687,DB01233,Metoclopramide
,18165446,Cmax,"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],9.28,37688,DB01233,Metoclopramide
,18165446,C(60),"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],9.62,37689,DB01233,Metoclopramide
,18165446,C(60),"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],6.08,37690,DB01233,Metoclopramide
,18165446,AUC(0-60),"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [h·l],10.01,37691,DB01233,Metoclopramide
,18165446,AUC(0-60),"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [h·l],3.93,37692,DB01233,Metoclopramide
,18165446,Tmax,"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),h,0.81,37693,DB01233,Metoclopramide
,18165446,Tmax,"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),h,1.98,37694,DB01233,Metoclopramide
,18165446,Cmax,"After prokinetic therapy, Cmax (15.26 +/- 8.85 mg/L), C(60) (11.96 +/- 5.99 mg/L), and AUC(0-60) (10.90 +/- 6.57 mg/h/L) increased and Tmax (1.07 +/- 1.01 hours) decreased in the intolerant group to values similar to the tolerant group.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],15.26,37695,DB01233,Metoclopramide
,18165446,C(60),"After prokinetic therapy, Cmax (15.26 +/- 8.85 mg/L), C(60) (11.96 +/- 5.99 mg/L), and AUC(0-60) (10.90 +/- 6.57 mg/h/L) increased and Tmax (1.07 +/- 1.01 hours) decreased in the intolerant group to values similar to the tolerant group.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],11.96,37696,DB01233,Metoclopramide
,18165446,AUC(0-60),"After prokinetic therapy, Cmax (15.26 +/- 8.85 mg/L), C(60) (11.96 +/- 5.99 mg/L), and AUC(0-60) (10.90 +/- 6.57 mg/h/L) increased and Tmax (1.07 +/- 1.01 hours) decreased in the intolerant group to values similar to the tolerant group.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [h·l],10.90,37697,DB01233,Metoclopramide
,18165446,Tmax,"After prokinetic therapy, Cmax (15.26 +/- 8.85 mg/L), C(60) (11.96 +/- 5.99 mg/L), and AUC(0-60) (10.90 +/- 6.57 mg/h/L) increased and Tmax (1.07 +/- 1.01 hours) decreased in the intolerant group to values similar to the tolerant group.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),h,1.07,37698,DB01233,Metoclopramide
,3542335,total body clearance,"The mean values for total body clearance and terminal half-life range from 0.31 to 0.69 L/kg/h and from 4.5 to 8.8 hours, respectively.",Pharmacokinetics of high-dose metoclopramide in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542335/),[l] / [h·kg],0.31 to 0.69,40833,DB01233,Metoclopramide
,3542335,terminal half-life,"The mean values for total body clearance and terminal half-life range from 0.31 to 0.69 L/kg/h and from 4.5 to 8.8 hours, respectively.",Pharmacokinetics of high-dose metoclopramide in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542335/),h,4.5 to 8.8,40834,DB01233,Metoclopramide
,8405031,terminal half-life,The terminal half-life of batanopride was significantly prolonged from 2.7 h in group 1 to 9.9 h in group 3.,The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405031/),h,2.7,44172,DB01233,Metoclopramide
,8405031,terminal half-life,The terminal half-life of batanopride was significantly prolonged from 2.7 h in group 1 to 9.9 h in group 3.,The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405031/),h,9.9,44173,DB01233,Metoclopramide
,8405031,renal clearance,The renal clearance of batanopride was significantly lower in group 3 (25 ml.min-1) compared with group 1 (132 ml.min-1).,The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405031/),[ml] / [min],25,44174,DB01233,Metoclopramide
,8405031,renal clearance,The renal clearance of batanopride was significantly lower in group 3 (25 ml.min-1) compared with group 1 (132 ml.min-1).,The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405031/),[ml] / [min],132,44175,DB01233,Metoclopramide
,6470977,bioavailability,"Intravenous administration of sulfinpyrazone demonstrated that the tablets had a high bioavailability (about 90%), and the time to peak plasma concentration of the sulfide and the amount formed were similar to those seen after oral administration.",Role of the gut flora in the reduction of sulfinpyrazone in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470977/),%,90,47919,DB01233,Metoclopramide
,7039926,systemic bioavailability,"Following oral administration it is rapidly absorbed from the gastrointestinal tract, its systemic bioavailability being dose-dependent and ranging from 70 to 90%.",Clinical pharmacokinetics of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),%,70 to 90,56310,DB01233,Metoclopramide
,7039926,volume of distribution,It distributes rapidly and evenly throughout most tissues and fluids and has a volume of distribution of approximately 0.9L/kg.,Clinical pharmacokinetics of paracetamol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[l] / [kg],0.9,56311,DB01233,Metoclopramide
,7039926,plasma half-life,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),h,1.9 to 2.5,56312,DB01233,Metoclopramide
,7039926,total body clearance,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[ml] / [kg·min],4.5 to 5.5,56313,DB01233,Metoclopramide
,7236872,time of peaking (tmax),Propantheline prolonged the absorption phase of atenolol and the time of peaking (tmax) was shifted from 2.1 to 4.5 h.,"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7236872/),h,2.1,56406,DB01233,Metoclopramide
,7236872,time of peaking (tmax),Propantheline prolonged the absorption phase of atenolol and the time of peaking (tmax) was shifted from 2.1 to 4.5 h.,"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7236872/),h,4.5,56407,DB01233,Metoclopramide
,3986303,Tmax,"PPB also increased Tmax from 2-8 h (p less than 0.001), and appeared to produce first order absorption of CGZ.",Bioavailability studies with ciglitazone in beagles. Effect of propantheline bromide and metoclopramide HCL on bioavailability of a tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986303/),h,2-8,56779,DB01233,Metoclopramide
,28814338,nausea behaviour score,The onset of nausea-like behaviour in the placebo-treated group occurred at t3.5h and peaked at t4.75h with nausea behaviour score of 58.5 ± 4.6 mm.,"Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),,58.5,57067,DB01233,Metoclopramide
,28814338,terminal half-lives,"The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.","Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),h,1.21,57068,DB01233,Metoclopramide
,28814338,terminal half-lives,"The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.","Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),h,5.62,57069,DB01233,Metoclopramide
,28814338,terminal half-lives,"The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.","Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),h,0.87,57070,DB01233,Metoclopramide
,8852049,limit of quantitation (LOQ),The limit of quantitation (LOQ) in human plasma is 2.5 ng ml-1 for both S-(-)- and R-(+)-amisulpride isomers with both detection methods.,"Stereospecific determination of amisulpride, a new benzamide derivative, in human plasma and urine by automated solid-phase extraction and liquid chromatography on a chiral column. application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852049/),[ng] / [ml],2.5,57548,DB01233,Metoclopramide
,1583079,peak serum concentrations,"The peak serum concentrations ranged from 402 to 5,608 ng/ml.",Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1583079/),[ng] / [ml],"402 to 5,608",61691,DB01233,Metoclopramide
,1583079,total clearance,"The total clearance and elimination half-life ranged from 0.03 to 0.28 (mean: 0.12) litre/kg/h, and from 1.2 to 15.5 (mean: 5.6) h, respectively.",Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1583079/),[l] / [h·kg],0.03 to 0.28,61692,DB01233,Metoclopramide
,1583079,total clearance,"The total clearance and elimination half-life ranged from 0.03 to 0.28 (mean: 0.12) litre/kg/h, and from 1.2 to 15.5 (mean: 5.6) h, respectively.",Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1583079/),[l] / [h·kg],0.12,61693,DB01233,Metoclopramide
,1583079,elimination half-life,"The total clearance and elimination half-life ranged from 0.03 to 0.28 (mean: 0.12) litre/kg/h, and from 1.2 to 15.5 (mean: 5.6) h, respectively.",Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1583079/),[l] / [h·kg],0.12,61694,DB01233,Metoclopramide
,1583079,elimination half-life,"The total clearance and elimination half-life ranged from 0.03 to 0.28 (mean: 0.12) litre/kg/h, and from 1.2 to 15.5 (mean: 5.6) h, respectively.",Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1583079/),h,5.6,61695,DB01233,Metoclopramide
,17348897,peak plasma concentration,"Cephalexin peak plasma concentration and area under the curve from 0 to infinity significantly increased from 18.77+/-2.8 microg/mL and 82.65+/-10.4 microg.h/mL to 21.88+/-0.8 microg/mL and 113.10+/-20.9 microg.h/mL, respectively, after pretreatment with metoclopramide.",Metoclopramide modifies oral cephalexin pharmacokinetics in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348897/),[μg] / [ml],18.77,64169,DB01233,Metoclopramide
,17348897,peak plasma concentration,"Cephalexin peak plasma concentration and area under the curve from 0 to infinity significantly increased from 18.77+/-2.8 microg/mL and 82.65+/-10.4 microg.h/mL to 21.88+/-0.8 microg/mL and 113.10+/-20.9 microg.h/mL, respectively, after pretreatment with metoclopramide.",Metoclopramide modifies oral cephalexin pharmacokinetics in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348897/),[μg] / [ml],21.88,64170,DB01233,Metoclopramide
,17348897,area under the curve from 0 to infinity,"Cephalexin peak plasma concentration and area under the curve from 0 to infinity significantly increased from 18.77+/-2.8 microg/mL and 82.65+/-10.4 microg.h/mL to 21.88+/-0.8 microg/mL and 113.10+/-20.9 microg.h/mL, respectively, after pretreatment with metoclopramide.",Metoclopramide modifies oral cephalexin pharmacokinetics in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348897/),[h·μg] / [ml],82.65,64171,DB01233,Metoclopramide
,17348897,area under the curve from 0 to infinity,"Cephalexin peak plasma concentration and area under the curve from 0 to infinity significantly increased from 18.77+/-2.8 microg/mL and 82.65+/-10.4 microg.h/mL to 21.88+/-0.8 microg/mL and 113.10+/-20.9 microg.h/mL, respectively, after pretreatment with metoclopramide.",Metoclopramide modifies oral cephalexin pharmacokinetics in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348897/),[h·μg] / [ml],113.10,64172,DB01233,Metoclopramide
,16962733,flow rate,The flow rate was 1 ml/min and the column temperature 45 degrees C.,Determination of loratadine and its active metabolite in human plasma by high-performance liquid chromatography with mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962733/),[ml] / [min],1,65841,DB01233,Metoclopramide
,2072291,peak metoclopramide concentration,Pharmacokinetic analysis showed mean peak metoclopramide concentration at 30 min of 99.7 +/- 47.1 ng/ml with measured levels of 93.9 +/- 106.83 ng/ml at 60 min and return to trough values by 4 hr; trough prolactins remained elevated above normal values.,Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072291/),[ng] / [ml],99.7,69591,DB01233,Metoclopramide
,2072291,peak metoclopramide concentration,Pharmacokinetic analysis showed mean peak metoclopramide concentration at 30 min of 99.7 +/- 47.1 ng/ml with measured levels of 93.9 +/- 106.83 ng/ml at 60 min and return to trough values by 4 hr; trough prolactins remained elevated above normal values.,Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072291/),ng,93.9,69592,DB01233,Metoclopramide
,34285598,Cmax,"Placebo-corrected, change from baseline in corrected QT interval at the observed geometric mean Cmax for trazpiroben alone (9.53 ng/mL) and with itraconazole (18.00 ng/mL) was estimated at 1.31 ms (-0.39, 3.01) and 1.54 ms (-0.15, 3.24), respectively.","Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285598/),[ng] / [ml],9.53,71178,DB01233,Metoclopramide
,34285598,Cmax,"Placebo-corrected, change from baseline in corrected QT interval at the observed geometric mean Cmax for trazpiroben alone (9.53 ng/mL) and with itraconazole (18.00 ng/mL) was estimated at 1.31 ms (-0.39, 3.01) and 1.54 ms (-0.15, 3.24), respectively.","Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285598/),[ng] / [ml],18.00,71179,DB01233,Metoclopramide
,34285598,Cmax,"Placebo-corrected, change from baseline in corrected QT interval at the observed geometric mean Cmax for trazpiroben alone (9.53 ng/mL) and with itraconazole (18.00 ng/mL) was estimated at 1.31 ms (-0.39, 3.01) and 1.54 ms (-0.15, 3.24), respectively.","Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285598/),ms,1.,71180,DB01233,Metoclopramide
,34285598,Cmax,"Placebo-corrected, change from baseline in corrected QT interval at the observed geometric mean Cmax for trazpiroben alone (9.53 ng/mL) and with itraconazole (18.00 ng/mL) was estimated at 1.31 ms (-0.39, 3.01) and 1.54 ms (-0.15, 3.24), respectively.","Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285598/),ms,1.54,71181,DB01233,Metoclopramide
,12754009,t(max),"The controlled release formula was found to be effective in delaying absorption (t(max) 4.5h as compared to 1.2h), reducing the peak plasma concentrations (C(max) 63.4 ng/ml as compared to 95.9 ng/ml) and maintaining higher concentrations during the elimination phase when compared to the immediate release formula.",Assessment of a controlled release hydrophilic matrix formulation for metoclopramide HCl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12754009/),h,4.5,74395,DB01233,Metoclopramide
,12754009,t(max),"The controlled release formula was found to be effective in delaying absorption (t(max) 4.5h as compared to 1.2h), reducing the peak plasma concentrations (C(max) 63.4 ng/ml as compared to 95.9 ng/ml) and maintaining higher concentrations during the elimination phase when compared to the immediate release formula.",Assessment of a controlled release hydrophilic matrix formulation for metoclopramide HCl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12754009/),h,1.2,74396,DB01233,Metoclopramide
,12754009,peak plasma concentrations (C(max),"The controlled release formula was found to be effective in delaying absorption (t(max) 4.5h as compared to 1.2h), reducing the peak plasma concentrations (C(max) 63.4 ng/ml as compared to 95.9 ng/ml) and maintaining higher concentrations during the elimination phase when compared to the immediate release formula.",Assessment of a controlled release hydrophilic matrix formulation for metoclopramide HCl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12754009/),[ng] / [ml],63.4,74397,DB01233,Metoclopramide
,12754009,peak plasma concentrations (C(max),"The controlled release formula was found to be effective in delaying absorption (t(max) 4.5h as compared to 1.2h), reducing the peak plasma concentrations (C(max) 63.4 ng/ml as compared to 95.9 ng/ml) and maintaining higher concentrations during the elimination phase when compared to the immediate release formula.",Assessment of a controlled release hydrophilic matrix formulation for metoclopramide HCl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12754009/),[ng] / [ml],95.9,74398,DB01233,Metoclopramide
,3730521,systemic clearance,"The systemic clearance of bromopride was 899 ml min-1 +/- 22 per cent CV, the volume of distribution was 2151 +/- 16 per cent CV, and the elimination half-life was 2.9 h +/- 21 per cent CV.",Pharmacokinetics and bioavailability of the anti-emetic agent bromopride. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730521/),[ml] / [min],899,74702,DB01233,Metoclopramide
,3730521,volume of distribution,"The systemic clearance of bromopride was 899 ml min-1 +/- 22 per cent CV, the volume of distribution was 2151 +/- 16 per cent CV, and the elimination half-life was 2.9 h +/- 21 per cent CV.",Pharmacokinetics and bioavailability of the anti-emetic agent bromopride. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730521/),%,2151,74703,DB01233,Metoclopramide
,3730521,elimination half-life,"The systemic clearance of bromopride was 899 ml min-1 +/- 22 per cent CV, the volume of distribution was 2151 +/- 16 per cent CV, and the elimination half-life was 2.9 h +/- 21 per cent CV.",Pharmacokinetics and bioavailability of the anti-emetic agent bromopride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730521/),h,2.9,74704,DB01233,Metoclopramide
,3730521,systemic availability,"The systemic availability of orally and intramuscularly administered solution doses of 20 mg of bromopride was 54 per cent and 78 per cent, respectively.",Pharmacokinetics and bioavailability of the anti-emetic agent bromopride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730521/),%,54,74705,DB01233,Metoclopramide
,3730521,systemic availability,"The systemic availability of orally and intramuscularly administered solution doses of 20 mg of bromopride was 54 per cent and 78 per cent, respectively.",Pharmacokinetics and bioavailability of the anti-emetic agent bromopride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730521/),%,78,74706,DB01233,Metoclopramide
,3730521,peak mean plasma drug concentrations,"No evidence for non-linear kinetics was found when bromopride was administered orally in the dose range 10-30 mg: after single oral doses of 10, 20, and 30 mg, peak mean plasma drug concentrations were 20 ng ml-1 +/- 32 per cent CV, 38 ng ml-1 +/- 16 per cent CV, and 64 ng ml-1 +/- 23 per cent CV, respectively.",Pharmacokinetics and bioavailability of the anti-emetic agent bromopride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730521/),[ng] / [ml],20,74707,DB01233,Metoclopramide
,3730521,peak mean plasma drug concentrations,"No evidence for non-linear kinetics was found when bromopride was administered orally in the dose range 10-30 mg: after single oral doses of 10, 20, and 30 mg, peak mean plasma drug concentrations were 20 ng ml-1 +/- 32 per cent CV, 38 ng ml-1 +/- 16 per cent CV, and 64 ng ml-1 +/- 23 per cent CV, respectively.",Pharmacokinetics and bioavailability of the anti-emetic agent bromopride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730521/),[ng] / [ml],38,74708,DB01233,Metoclopramide
,3730521,peak mean plasma drug concentrations,"No evidence for non-linear kinetics was found when bromopride was administered orally in the dose range 10-30 mg: after single oral doses of 10, 20, and 30 mg, peak mean plasma drug concentrations were 20 ng ml-1 +/- 32 per cent CV, 38 ng ml-1 +/- 16 per cent CV, and 64 ng ml-1 +/- 23 per cent CV, respectively.",Pharmacokinetics and bioavailability of the anti-emetic agent bromopride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730521/),[ng] / [ml],64,74709,DB01233,Metoclopramide
,955840,maximum blood levels,In Groups I and II maximum blood levels were reached 2.1 +/- 0.4 or 2.0 +/- 0.4 h p. admin.,Influences on the rate of absorption of the cholecystographic contrast medium iosumetic acid in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/955840/),h,2.1,81844,DB01233,Metoclopramide
,955840,maximum blood levels,In Groups I and II maximum blood levels were reached 2.1 +/- 0.4 or 2.0 +/- 0.4 h p. admin.,Influences on the rate of absorption of the cholecystographic contrast medium iosumetic acid in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/955840/),h,2.0,81845,DB01233,Metoclopramide
,955840,half-life,A half-life of 0.3 +/- 0.1 h was calculated for absorption in Group IV.,Influences on the rate of absorption of the cholecystographic contrast medium iosumetic acid in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/955840/),h,0.3,81846,DB01233,Metoclopramide
,18596312,Cmax,"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[mg] / [l],9.5,83751,DB01233,Metoclopramide
,18596312,Cmax,"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[mg] / [l],17.7,83752,DB01233,Metoclopramide
,18596312,C(60),"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[mg] / [l],5.4,83753,DB01233,Metoclopramide
,18596312,C(60),"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[mg] / [l],12.9,83754,DB01233,Metoclopramide
,18596312,AUC(0-60),"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[h·mg] / [l],3.5,83755,DB01233,Metoclopramide
,18596312,AUC(0-60),"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[h·mg] / [l],12.5,83756,DB01233,Metoclopramide
,18596312,AUC(0-60),"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[h·mg] / [l],4.4,83757,DB01233,Metoclopramide
,18596312,AUC(0-60),"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[h·mg] / [l],9.5,83758,DB01233,Metoclopramide
,18596312,residual volumes,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),ml,122,83759,DB01233,Metoclopramide
,18596312,residual volumes,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),ml,36,83760,DB01233,Metoclopramide
,18596312,residual volumes,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),ml,103,83761,DB01233,Metoclopramide
,18596312,residual volumes,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),ml,21,83762,DB01233,Metoclopramide
,18596312,feeding rates,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[ml] / [h],17,83763,DB01233,Metoclopramide
,18596312,feeding rates,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[ml] / [h],45,83764,DB01233,Metoclopramide
,18596312,feeding rates,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[ml] / [h],14,83765,DB01233,Metoclopramide
,18596312,feeding rates,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[ml] / [h],44,83766,DB01233,Metoclopramide
,3928960,serum level,"When the drug was infused, forced diuresis had no influence on the pharmacokinetics of metoclopramide (serum level after the 1st infusion was 851 +/- 361 ng/ml in group A versus 840 +/- 348 ng/ml in group B; after the 5th infusion it was 2,005 +/- 588 ng/ml in group A versus 2,463 +/- 1,350 ng/ml in group B).",Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3928960/),[ng] / [ml],851,84493,DB01233,Metoclopramide
,3928960,serum level,"When the drug was infused, forced diuresis had no influence on the pharmacokinetics of metoclopramide (serum level after the 1st infusion was 851 +/- 361 ng/ml in group A versus 840 +/- 348 ng/ml in group B; after the 5th infusion it was 2,005 +/- 588 ng/ml in group A versus 2,463 +/- 1,350 ng/ml in group B).",Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3928960/),[ng] / [ml],840,84494,DB01233,Metoclopramide
,3928960,serum level,"When the drug was infused, forced diuresis had no influence on the pharmacokinetics of metoclopramide (serum level after the 1st infusion was 851 +/- 361 ng/ml in group A versus 840 +/- 348 ng/ml in group B; after the 5th infusion it was 2,005 +/- 588 ng/ml in group A versus 2,463 +/- 1,350 ng/ml in group B).",Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3928960/),[ng] / [ml],"2,005",84495,DB01233,Metoclopramide
,3928960,serum level,"When the drug was infused, forced diuresis had no influence on the pharmacokinetics of metoclopramide (serum level after the 1st infusion was 851 +/- 361 ng/ml in group A versus 840 +/- 348 ng/ml in group B; after the 5th infusion it was 2,005 +/- 588 ng/ml in group A versus 2,463 +/- 1,350 ng/ml in group B).",Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3928960/),[ng] / [ml],"2,463",84496,DB01233,Metoclopramide
,3928960,serum levels,There were significant differences in the 24-h serum levels (582 +/- 308 ng/ml in group A versus 379 +/- 170 ng/ml in group B; P less than 0.05) and in the elimination half life (8.5 +/- 2.6 h in group A versus 6.1 +/- 1.1 h in group B; P less than 0.05).,Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3928960/),[ng] / [ml],582,84497,DB01233,Metoclopramide
,3928960,serum levels,There were significant differences in the 24-h serum levels (582 +/- 308 ng/ml in group A versus 379 +/- 170 ng/ml in group B; P less than 0.05) and in the elimination half life (8.5 +/- 2.6 h in group A versus 6.1 +/- 1.1 h in group B; P less than 0.05).,Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3928960/),[ng] / [ml],379,84498,DB01233,Metoclopramide
,3928960,elimination half life,There were significant differences in the 24-h serum levels (582 +/- 308 ng/ml in group A versus 379 +/- 170 ng/ml in group B; P less than 0.05) and in the elimination half life (8.5 +/- 2.6 h in group A versus 6.1 +/- 1.1 h in group B; P less than 0.05).,Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3928960/),h,8.5,84499,DB01233,Metoclopramide
,3928960,elimination half life,There were significant differences in the 24-h serum levels (582 +/- 308 ng/ml in group A versus 379 +/- 170 ng/ml in group B; P less than 0.05) and in the elimination half life (8.5 +/- 2.6 h in group A versus 6.1 +/- 1.1 h in group B; P less than 0.05).,Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3928960/),h,6.1,84500,DB01233,Metoclopramide
,16770757,peak plasma concentrations (Cmax),"In the two periods of treatment, the mean peak plasma concentrations (Cmax) were 44.02 ng/ml (metoclopramide alone) and 62.72 ng/ml (metoclopramide after pre-treatment with fluoxetine).",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),[ng] / [ml],44.02,84654,DB01233,Metoclopramide
,16770757,peak plasma concentrations (Cmax),"In the two periods of treatment, the mean peak plasma concentrations (Cmax) were 44.02 ng/ml (metoclopramide alone) and 62.72 ng/ml (metoclopramide after pre-treatment with fluoxetine).",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),[ng] / [ml],62.72,84655,DB01233,Metoclopramide
,16770757,Cmax,"The times taken to reach Cmax and tmax, were 1.15 h and 1.06 h, respectively.",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),h,1.15,84656,DB01233,Metoclopramide
,16770757,tmax,"The times taken to reach Cmax and tmax, were 1.15 h and 1.06 h, respectively.",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),h,1.06,84657,DB01233,Metoclopramide
,16770757,areas under the curve (AUC(0-infinity)),"The total areas under the curve (AUC(0-infinity)) were 312.61 ng.h/ml and 590.62 ng.h/ml, respectively.",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),[h·ng] / [ml],312.61,84658,DB01233,Metoclopramide
,16770757,areas under the curve (AUC(0-infinity)),"The total areas under the curve (AUC(0-infinity)) were 312.61 ng.h/ml and 590.62 ng.h/ml, respectively.",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),[h·ng] / [ml],590.62,84659,DB01233,Metoclopramide
,16770757,half-life values (t1/2),The half-life values (t1/2) were 5.52 h and 8.47 h.,Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),h,5.52,84660,DB01233,Metoclopramide
,16770757,half-life values (t1/2),The half-life values (t1/2) were 5.52 h and 8.47 h.,Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),h,8.47,84661,DB01233,Metoclopramide
,7196237,Bioavailabilities,Bioavailabilities between 76 and 79% were determined for the oral application forms and 53% for the rectal application form.,"The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7196237/),%,76 and 79,87080,DB01233,Metoclopramide
,7196237,Bioavailabilities,Bioavailabilities between 76 and 79% were determined for the oral application forms and 53% for the rectal application form.,"The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7196237/),%,53,87081,DB01233,Metoclopramide
,7196237,elimination half-lives,"The initial distribution of the drug is very rapid, and the elimination half-lives are comparable for all formulations and ranged from 3.9 and 5.3 h.","The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7196237/),h,3.9,87082,DB01233,Metoclopramide
,7196237,elimination half-lives,"The initial distribution of the drug is very rapid, and the elimination half-lives are comparable for all formulations and ranged from 3.9 and 5.3 h.","The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7196237/),h,5.3,87083,DB01233,Metoclopramide
,7196237,apparent volume of distribution,The apparent volume of distribution is 3.1 l/kg body weight and the total body clearance is 38.4 l/h.,"The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7196237/),[l] / [body·kg·weight],3.1,87084,DB01233,Metoclopramide
,7196237,total body clearance,The apparent volume of distribution is 3.1 l/kg body weight and the total body clearance is 38.4 l/h.,"The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7196237/),[l] / [h],38.4,87085,DB01233,Metoclopramide
,4027119,clearance,"Mean clearance was 0.33 +/- 0.13 (s.d.) l h-1 kg-1, mean volume of distribution at steady state was 3.8 +/- 1.2 (s.d.) l/kg and mean elimination half-life was 8.3 +/- 4.4 (s.d.) h.",The pharmacokinetics of high dose metoclopramide in patients with neoplastic disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027119/),[l] / [h·kg],0.33,89331,DB01233,Metoclopramide
,4027119,volume of distribution at steady state,"Mean clearance was 0.33 +/- 0.13 (s.d.) l h-1 kg-1, mean volume of distribution at steady state was 3.8 +/- 1.2 (s.d.) l/kg and mean elimination half-life was 8.3 +/- 4.4 (s.d.) h.",The pharmacokinetics of high dose metoclopramide in patients with neoplastic disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027119/),[l] / [kg],3.8,89332,DB01233,Metoclopramide
,4027119,elimination half-life,"Mean clearance was 0.33 +/- 0.13 (s.d.) l h-1 kg-1, mean volume of distribution at steady state was 3.8 +/- 1.2 (s.d.) l/kg and mean elimination half-life was 8.3 +/- 4.4 (s.d.) h.",The pharmacokinetics of high dose metoclopramide in patients with neoplastic disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027119/),h,8.3,89333,DB01233,Metoclopramide
,1379152,half-life,It is likely that migraine recurrence is related to the short half-life of the drug (approximately 2 hours).,"Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379152/),h,2,90807,DB01233,Metoclopramide
,9705120,Tmax,"In the control group, Tmax was 31 min and this decreased significantly (P < 0.05) following the administration of metoclopramide.",Acetaminophen as a marker of gastric emptying in ponies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9705120/),min,31,102516,DB01233,Metoclopramide
,9646009,concentration ratio (UV/MV),The umbilical/maternal vein concentration ratio (UV/MV) of nondepolarising neuromuscular relaxants varies from 7 to 26% and clinical doses of these drugs may induce partial residual curarisation in neonates.,Clinical pharmacokinetics of neuromuscular relaxants in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646009/),%,7 to 26,106950,DB01233,Metoclopramide
,2778095,Cmax,The pharmacokinetic parameters of droxicam were: Cmax = 1.03 +/- 0.16 micrograms/mL (mean +/- SD).,The influence of gastric emptying on droxicam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),[μg] / [ml],1.03,107248,DB01233,Metoclopramide
,2778095,Tmax,"Tmax = 11.1 +/- 5.7 hr, AUC = 115.7 +/- 29.6 micrograms hr/mL, T 1/2 a = 2.64 +/- 0.72 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,11.1,107249,DB01233,Metoclopramide
,2778095,AUC,"Tmax = 11.1 +/- 5.7 hr, AUC = 115.7 +/- 29.6 micrograms hr/mL, T 1/2 a = 2.64 +/- 0.72 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),[h·μg] / [ml],115.7,107250,DB01233,Metoclopramide
,2778095,T 1/2 a,"Tmax = 11.1 +/- 5.7 hr, AUC = 115.7 +/- 29.6 micrograms hr/mL, T 1/2 a = 2.64 +/- 0.72 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,2.64,107251,DB01233,Metoclopramide
,2778095,T 1/2 el,"T 1/2 el = 73.6 +/- 16.7 hr, CL/F = 3.06 +/- 0.80 mL/min and MRT = 111.1 +/- 23.5 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,73.6,107252,DB01233,Metoclopramide
,2778095,CL/F,"T 1/2 el = 73.6 +/- 16.7 hr, CL/F = 3.06 +/- 0.80 mL/min and MRT = 111.1 +/- 23.5 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),[ml] / [min],3.06,107253,DB01233,Metoclopramide
,2778095,MRT,"T 1/2 el = 73.6 +/- 16.7 hr, CL/F = 3.06 +/- 0.80 mL/min and MRT = 111.1 +/- 23.5 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,111.1,107254,DB01233,Metoclopramide
,2778095,Tmax,"Following modification of gastric emptying, only Tmax (droxicam + metoclopramide = 25.0 +/- 10.8 hr and droxicam + propantheline = 20.8 +/- 8.8 hr) underwent significant change (P less than 0.05).",The influence of gastric emptying on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,25.0,107255,DB01233,Metoclopramide
,2778095,Tmax,"Following modification of gastric emptying, only Tmax (droxicam + metoclopramide = 25.0 +/- 10.8 hr and droxicam + propantheline = 20.8 +/- 8.8 hr) underwent significant change (P less than 0.05).",The influence of gastric emptying on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,20.8,107256,DB01233,Metoclopramide
,3190997,absolute bioavailability,The absolute bioavailability of metoclopramide was 0.76 +/- 0.38 (mean +/- s.d.) from the oral dosage forms examined in this study.,Linearity of metoclopramide kinetics at doses of 5-20 mg. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190997/),,0.76,109779,DB01233,Metoclopramide
,3242579,Cmax,"3. In the minor surgery group after Gastrobid Continus the plasma drug concentration-time curve was wider at half Cmax (P less than 0.01), Cmax was reduced (P less than 0.05) and delayed (median (range) 4 (3-6) vs 2.5 (2-4) h) compared with Maxolon, and the log of the metoclopramide concentration did not have a linear relationship with time from 2-9 h.",A single dose pharmacokinetic study of Gastrobid Continus and Maxolon in the perioperative period. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3242579/),h,4,110567,DB01233,Metoclopramide
,3242579,Cmax,"3. In the minor surgery group after Gastrobid Continus the plasma drug concentration-time curve was wider at half Cmax (P less than 0.01), Cmax was reduced (P less than 0.05) and delayed (median (range) 4 (3-6) vs 2.5 (2-4) h) compared with Maxolon, and the log of the metoclopramide concentration did not have a linear relationship with time from 2-9 h.",A single dose pharmacokinetic study of Gastrobid Continus and Maxolon in the perioperative period. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3242579/),h,2.5,110568,DB01233,Metoclopramide
,19935799,half-life,"Spectra were obtained immediately post infusion (MRS no. 1), at 16 h (MRS no. 2) and 20 h (MRS no. 3), based on the SR4554 half-life of 3.5 h determined from a previous study.",A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935799/),h,3.5,112264,DB01233,Metoclopramide
,19935799,plasma elimination half-life,SR4554 was well tolerated and toxicities were all < or = grade 1; mean plasma elimination half-life was 3.7+/-0.9 h.,A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935799/),h,3.7,112265,DB01233,Metoclopramide
,19935799,retention index,"Localised 19F signals were detected at MRS no. 2 in 5 out of 9 patients and 4 out of 5 patients at MRS no. 3. The mean retention index in tumour was 13.6 (range 0.6-43.7) compared with 4.1 (range 0.6-7.3) for plasma samples taken at the same times (P=0.001) suggesting (19)F retention in tumour and, therefore, the presence of hypoxia.",A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935799/),,13.6,112266,DB01233,Metoclopramide
,19935799,retention index,"Localised 19F signals were detected at MRS no. 2 in 5 out of 9 patients and 4 out of 5 patients at MRS no. 3. The mean retention index in tumour was 13.6 (range 0.6-43.7) compared with 4.1 (range 0.6-7.3) for plasma samples taken at the same times (P=0.001) suggesting (19)F retention in tumour and, therefore, the presence of hypoxia.",A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935799/),,4.1,112267,DB01233,Metoclopramide
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB01233,Metoclopramide
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB01233,Metoclopramide
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB01233,Metoclopramide
,3580027,area under the plasma metoclopramide level-time curve (AUC),The area under the plasma metoclopramide level-time curve (AUC) values showed that the products were bioequivalent with the mean AUC values for the capsule (0-24 h) 837.9 ng/h/ml and (120-150 h) 993.2 ng/h/ml; and for the solution (0-24 h) 878.8 ng/h/ml and (120-150 h) 1054.0 ng/h/ml.,Bioavailability of controlled-release metoclopramide. 2nd communication: multiple dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580027/),[ng] / [h·ml],837.9,116694,DB01233,Metoclopramide
,3580027,AUC,The area under the plasma metoclopramide level-time curve (AUC) values showed that the products were bioequivalent with the mean AUC values for the capsule (0-24 h) 837.9 ng/h/ml and (120-150 h) 993.2 ng/h/ml; and for the solution (0-24 h) 878.8 ng/h/ml and (120-150 h) 1054.0 ng/h/ml.,Bioavailability of controlled-release metoclopramide. 2nd communication: multiple dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580027/),[ng] / [h·ml],837.9,116695,DB01233,Metoclopramide
,3580027,AUC,The area under the plasma metoclopramide level-time curve (AUC) values showed that the products were bioequivalent with the mean AUC values for the capsule (0-24 h) 837.9 ng/h/ml and (120-150 h) 993.2 ng/h/ml; and for the solution (0-24 h) 878.8 ng/h/ml and (120-150 h) 1054.0 ng/h/ml.,Bioavailability of controlled-release metoclopramide. 2nd communication: multiple dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580027/),[ng] / [h·ml],993.2,116696,DB01233,Metoclopramide
,3580027,AUC,The area under the plasma metoclopramide level-time curve (AUC) values showed that the products were bioequivalent with the mean AUC values for the capsule (0-24 h) 837.9 ng/h/ml and (120-150 h) 993.2 ng/h/ml; and for the solution (0-24 h) 878.8 ng/h/ml and (120-150 h) 1054.0 ng/h/ml.,Bioavailability of controlled-release metoclopramide. 2nd communication: multiple dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580027/),[ng] / [h·ml],878.8,116697,DB01233,Metoclopramide
,3580027,AUC,The area under the plasma metoclopramide level-time curve (AUC) values showed that the products were bioequivalent with the mean AUC values for the capsule (0-24 h) 837.9 ng/h/ml and (120-150 h) 993.2 ng/h/ml; and for the solution (0-24 h) 878.8 ng/h/ml and (120-150 h) 1054.0 ng/h/ml.,Bioavailability of controlled-release metoclopramide. 2nd communication: multiple dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580027/),[ng] / [h·ml],1054.0,116698,DB01233,Metoclopramide
,3580027,0-24 h,The area under the plasma metoclopramide level-time curve (AUC) values showed that the products were bioequivalent with the mean AUC values for the capsule (0-24 h) 837.9 ng/h/ml and (120-150 h) 993.2 ng/h/ml; and for the solution (0-24 h) 878.8 ng/h/ml and (120-150 h) 1054.0 ng/h/ml.,Bioavailability of controlled-release metoclopramide. 2nd communication: multiple dose study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580027/),[ng] / [h·ml],837.9,116699,DB01233,Metoclopramide
,3580027,0-24 h,The area under the plasma metoclopramide level-time curve (AUC) values showed that the products were bioequivalent with the mean AUC values for the capsule (0-24 h) 837.9 ng/h/ml and (120-150 h) 993.2 ng/h/ml; and for the solution (0-24 h) 878.8 ng/h/ml and (120-150 h) 1054.0 ng/h/ml.,Bioavailability of controlled-release metoclopramide. 2nd communication: multiple dose study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580027/),[ng] / [h·ml],993.2,116700,DB01233,Metoclopramide
,3580027,0-24 h,The area under the plasma metoclopramide level-time curve (AUC) values showed that the products were bioequivalent with the mean AUC values for the capsule (0-24 h) 837.9 ng/h/ml and (120-150 h) 993.2 ng/h/ml; and for the solution (0-24 h) 878.8 ng/h/ml and (120-150 h) 1054.0 ng/h/ml.,Bioavailability of controlled-release metoclopramide. 2nd communication: multiple dose study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580027/),[ng] / [h·ml],878.8,116701,DB01233,Metoclopramide
,3580027,0-24 h,The area under the plasma metoclopramide level-time curve (AUC) values showed that the products were bioequivalent with the mean AUC values for the capsule (0-24 h) 837.9 ng/h/ml and (120-150 h) 993.2 ng/h/ml; and for the solution (0-24 h) 878.8 ng/h/ml and (120-150 h) 1054.0 ng/h/ml.,Bioavailability of controlled-release metoclopramide. 2nd communication: multiple dose study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580027/),[ng] / [h·ml],1054.0,116702,DB01233,Metoclopramide
,1647955,mean plasma concentration,"The mean plasma concentration at the end of the infusion in the adjusted group was 1.01 mg.l-1, close to that aimed for (1.20 mg.l-1).",Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1647955/),[mg] / [l],1.01,116729,DB01233,Metoclopramide
,1647955,mean plasma concentration,"The mean plasma concentration at the end of the infusion in the adjusted group was 1.01 mg.l-1, close to that aimed for (1.20 mg.l-1).",Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1647955/),[mg] / [l],1.20,116730,DB01233,Metoclopramide
,728283,T1/2alpha,It is proposed that a two-compartment model adequately describes the disposition of the drug which is rapidly distributed (T1/2alpha = 4.9 +/- 1.1 min) and eliminated (T1/2beta = 165.7 +/- 20.2 min).,Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/728283/),min,4.9,122408,DB01233,Metoclopramide
,728283,T1/2beta,It is proposed that a two-compartment model adequately describes the disposition of the drug which is rapidly distributed (T1/2alpha = 4.9 +/- 1.1 min) and eliminated (T1/2beta = 165.7 +/- 20.2 min).,Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/728283/),min,165.7,122409,DB01233,Metoclopramide
,728283,Total body plasma clearance,Total body plasma clearance of the drug is high (10.9 +/- 1.5 ml min-1 kg-1) and approximates to liver plasma flow.,Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/728283/),[ml] / [kg·min],10.9,122410,DB01233,Metoclopramide
,8040934,oral,"The mean (+/- SD) oral and abomasal bioavailabilities were 51.3 +/- 30.7% and 76.2 +/- 15.5%, respectively.",Bioavailability and pharmacokinetics of metoclopramide in cattle. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040934/),%,51.3,124418,DB01233,Metoclopramide
,8040934,bioavailabilities,"The mean (+/- SD) oral and abomasal bioavailabilities were 51.3 +/- 30.7% and 76.2 +/- 15.5%, respectively.",Bioavailability and pharmacokinetics of metoclopramide in cattle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040934/),%,76.2,124419,DB01233,Metoclopramide
,8040934,clearance (Cl),The mean value for clearance (Cl) was 20.1 +/- 5.9 ml/min and the volume of distribution (Vd) was 0.51 +/- 0.19 l/kg.,Bioavailability and pharmacokinetics of metoclopramide in cattle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040934/),[ml] / [min],20.1,124420,DB01233,Metoclopramide
,8040934,volume of distribution (Vd),The mean value for clearance (Cl) was 20.1 +/- 5.9 ml/min and the volume of distribution (Vd) was 0.51 +/- 0.19 l/kg.,Bioavailability and pharmacokinetics of metoclopramide in cattle. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040934/),[l] / [kg],0.51,124421,DB01233,Metoclopramide
,8040934,t 1/2 alpha,"A predominate two-compartment model of distribution was found in six cows with a t 1/2 alpha harmonic mean of 24.2 min and a range of 11.2-72.4 min, a t 1/2 beta harmonic mean of 53.1 min and a range of 31.1-134.1 min, a Cl of 42.2 +/- 8.7 ml/min, and a Vd of 2.1 +/- 0.8 l/kg.",Bioavailability and pharmacokinetics of metoclopramide in cattle. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040934/),min,24.2,124422,DB01233,Metoclopramide
,8040934,t 1/2 beta,"A predominate two-compartment model of distribution was found in six cows with a t 1/2 alpha harmonic mean of 24.2 min and a range of 11.2-72.4 min, a t 1/2 beta harmonic mean of 53.1 min and a range of 31.1-134.1 min, a Cl of 42.2 +/- 8.7 ml/min, and a Vd of 2.1 +/- 0.8 l/kg.",Bioavailability and pharmacokinetics of metoclopramide in cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040934/),min,53.1,124423,DB01233,Metoclopramide
,8040934,Cl,"A predominate two-compartment model of distribution was found in six cows with a t 1/2 alpha harmonic mean of 24.2 min and a range of 11.2-72.4 min, a t 1/2 beta harmonic mean of 53.1 min and a range of 31.1-134.1 min, a Cl of 42.2 +/- 8.7 ml/min, and a Vd of 2.1 +/- 0.8 l/kg.",Bioavailability and pharmacokinetics of metoclopramide in cattle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040934/),[ml] / [min],42.2,124424,DB01233,Metoclopramide
,8040934,Vd,"A predominate two-compartment model of distribution was found in six cows with a t 1/2 alpha harmonic mean of 24.2 min and a range of 11.2-72.4 min, a t 1/2 beta harmonic mean of 53.1 min and a range of 31.1-134.1 min, a Cl of 42.2 +/- 8.7 ml/min, and a Vd of 2.1 +/- 0.8 l/kg.",Bioavailability and pharmacokinetics of metoclopramide in cattle. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040934/),[l] / [kg],2.1,124425,DB01233,Metoclopramide
,8040934,steady-state metoclopramide concentration (MCPss),A steady-state metoclopramide concentration (MCPss) of 8.8 +/- 2.6 ng/ml was associated with a three-fold elevation of prolactin to a mean value of 12.1 +/- 3.1 ng/ml in six yearling steers.,Bioavailability and pharmacokinetics of metoclopramide in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040934/),[ng] / [ml],8.8,124426,DB01233,Metoclopramide
,11996211,absolute bioavailability,The absolute bioavailability of the sustained release formulation (fasting state) was 58% and thus about 17% lower than the bioavailability of the immediate release formulation.,Analysis of formulation and food effect on the absorption of metoclopramide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996211/),%,58,124700,DB01233,Metoclopramide
,11996211,absolute bioavailability,The absolute bioavailability of the sustained release formulation (fasting state) was 58% and thus about 17% lower than the bioavailability of the immediate release formulation.,Analysis of formulation and food effect on the absorption of metoclopramide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996211/),%,17,124701,DB01233,Metoclopramide
,23149484,m/z,"MCP and levosulpiride (internal standard) were analyzed in the precursor/product ion pair of m/z 300.1/226.9 and 342.0/112.0, respectively.",Simple and sensitive method for measurement of metoclopramide in cattle plasma by LC-MS/MS using a multimode chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149484/),,300.1,125545,DB01233,Metoclopramide
,23149484,m/z,"MCP and levosulpiride (internal standard) were analyzed in the precursor/product ion pair of m/z 300.1/226.9 and 342.0/112.0, respectively.",Simple and sensitive method for measurement of metoclopramide in cattle plasma by LC-MS/MS using a multimode chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149484/),,226.9,125546,DB01233,Metoclopramide
,23149484,m/z,"MCP and levosulpiride (internal standard) were analyzed in the precursor/product ion pair of m/z 300.1/226.9 and 342.0/112.0, respectively.",Simple and sensitive method for measurement of metoclopramide in cattle plasma by LC-MS/MS using a multimode chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149484/),,342.0,125547,DB01233,Metoclopramide
,23149484,m/z,"MCP and levosulpiride (internal standard) were analyzed in the precursor/product ion pair of m/z 300.1/226.9 and 342.0/112.0, respectively.",Simple and sensitive method for measurement of metoclopramide in cattle plasma by LC-MS/MS using a multimode chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149484/),,112.0,125548,DB01233,Metoclopramide
,23149484,recoveries,"Mean recoveries were 96-103%, and the coefficient of variation was less than 6.5%.",Simple and sensitive method for measurement of metoclopramide in cattle plasma by LC-MS/MS using a multimode chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149484/),%,96-103,125549,DB01233,Metoclopramide
,7378253,plasma beta half-life,The mean plasma beta half-life was 156.7 min after i.v. administration of 10 mg metoclopramide.,The pharmacokinetics of metoclopramide in man with observations in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378253/),min,156.7,125764,DB01233,Metoclopramide
,7378253,half-life,3 After oral dosing of 10 mg the mean half-life was 196.6 min and after 20 mg 317.5 min (P less than 0.05).,The pharmacokinetics of metoclopramide in man with observations in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378253/),min,196.6,125765,DB01233,Metoclopramide
,7378253,half-life,3 After oral dosing of 10 mg the mean half-life was 196.6 min and after 20 mg 317.5 min (P less than 0.05).,The pharmacokinetics of metoclopramide in man with observations in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378253/),min,317.5,125766,DB01233,Metoclopramide
,7378253,Bioavailability,4 Bioavailability of a 10 mg oral dose of metoclopramide varied between 32 and 97%.,The pharmacokinetics of metoclopramide in man with observations in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378253/),%,32 and 97,125767,DB01233,Metoclopramide
,1838490,biodisponibility,"The pharmacokinetics of the drug are as follows: absorption begins about 30 minutes after the administration per os, its biodisponibility is about 60%, its clearance: 20 ml/minute and its elimination half life about 3 hours.","[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1838490/),%,60,126480,DB01233,Metoclopramide
,1838490,clearance,"The pharmacokinetics of the drug are as follows: absorption begins about 30 minutes after the administration per os, its biodisponibility is about 60%, its clearance: 20 ml/minute and its elimination half life about 3 hours.","[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1838490/),[ml] / [min],20,126481,DB01233,Metoclopramide
,1838490,elimination half life,"The pharmacokinetics of the drug are as follows: absorption begins about 30 minutes after the administration per os, its biodisponibility is about 60%, its clearance: 20 ml/minute and its elimination half life about 3 hours.","[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1838490/),h,3,126482,DB01233,Metoclopramide
,26580822,flow rate,"The final mobile phase consisted of ACN:AcONH4 (20 mM) solution, pH 4 (70:30, v/v) at a flow rate of 1 mL/min.",Detection and quantification of the selective EP4 receptor antagonist CJ-023423 (grapiprant) in canine plasma by HPLC with spectrofluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580822/),[ml] / [min],1,128611,DB01233,Metoclopramide
,26580822,recovery,"Grapiprant was extracted from the plasma using CHCl3, which gave a recovery of 88.1 ± 10.22% and a lower limit of quantification (LLOQ) of 10 ng/mL.",Detection and quantification of the selective EP4 receptor antagonist CJ-023423 (grapiprant) in canine plasma by HPLC with spectrofluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580822/),%,88.1,128612,DB01233,Metoclopramide
,31903824,GS,"The results revealed that the MCP HCl-LS; composed of PF127/PF68/HPMC (20/7/0.5% w/w) was in the liquid state at room temperature, experienced gelation at 30.23 °C, with suitable GS of 28.66 s and rectal retention force of 43.03 × 102 dyne/cm2.",Mucoadhesive thermoreversible formulation of metoclopramide for rectal administration: a promising strategy for potential management of chemotherapy-induced nausea and vomiting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31903824/),s,28.66,130554,DB01233,Metoclopramide
,31903824,rectal retention force,"The results revealed that the MCP HCl-LS; composed of PF127/PF68/HPMC (20/7/0.5% w/w) was in the liquid state at room temperature, experienced gelation at 30.23 °C, with suitable GS of 28.66 s and rectal retention force of 43.03 × 102 dyne/cm2.",Mucoadhesive thermoreversible formulation of metoclopramide for rectal administration: a promising strategy for potential management of chemotherapy-induced nausea and vomiting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31903824/),[dyne] / [cm2],43.03 × 102,130555,DB01233,Metoclopramide
,31903824,AUC0-480,"The pharmacokinetic data showed that the MCP HCl-LS exhibited a significant increase (p < 0.05) in AUC0-480 (219.688 vs 172.333 ng.h.mL-1 of the marketed) and 1.3-fold increase in relative bioavailability compared to Primperan® suppository, indicating that LS formula bypassed the first-pass metabolism.",Mucoadhesive thermoreversible formulation of metoclopramide for rectal administration: a promising strategy for potential management of chemotherapy-induced nausea and vomiting. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31903824/),[h·ng] / [ml],219.688,130556,DB01233,Metoclopramide
,31903824,AUC0-480,"The pharmacokinetic data showed that the MCP HCl-LS exhibited a significant increase (p < 0.05) in AUC0-480 (219.688 vs 172.333 ng.h.mL-1 of the marketed) and 1.3-fold increase in relative bioavailability compared to Primperan® suppository, indicating that LS formula bypassed the first-pass metabolism.",Mucoadhesive thermoreversible formulation of metoclopramide for rectal administration: a promising strategy for potential management of chemotherapy-induced nausea and vomiting. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31903824/),[h·ng] / [ml],172.333,130557,DB01233,Metoclopramide
,6511853,limit of detection,"The limit of detection in plasma was 2 ng/ml, sufficient for pharmacokinetic studies of the drug.",Determination of bromopride in human plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511853/),[ng] / [ml],2,130613,DB01233,Metoclopramide
,6511853,peak levels,Plasma concentrations of bromopride reached mean peak levels (55 ng/ml) at 1 h after single oral doses of 20 mg and declined with a half-life of 4.9 h.,Determination of bromopride in human plasma and urine by high-performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511853/),[ng] / [ml],55,130614,DB01233,Metoclopramide
,6511853,half-life,Plasma concentrations of bromopride reached mean peak levels (55 ng/ml) at 1 h after single oral doses of 20 mg and declined with a half-life of 4.9 h.,Determination of bromopride in human plasma and urine by high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511853/),h,4.9,130615,DB01233,Metoclopramide
,3582418,peak plasma concentration,"Metoclopramide reduced the peak plasma concentration of digoxin from 1.5 +/- 0.2 ng/ml to 1.1 +/- 0.1 ng/ml (mean +/- SEM) (p = 0.05), cisapride lowered the peak concentration to 1.3 +/- 0.1 ng/ml (p = 0.14).",Effect of cisapride and metoclopramide on digoxin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),[ng] / [ml],1.5,131947,DB01233,Metoclopramide
,3582418,peak plasma concentration,"Metoclopramide reduced the peak plasma concentration of digoxin from 1.5 +/- 0.2 ng/ml to 1.1 +/- 0.1 ng/ml (mean +/- SEM) (p = 0.05), cisapride lowered the peak concentration to 1.3 +/- 0.1 ng/ml (p = 0.14).",Effect of cisapride and metoclopramide on digoxin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),[ng] / [ml],1.1,131948,DB01233,Metoclopramide
,3582418,peak concentration,"Metoclopramide reduced the peak plasma concentration of digoxin from 1.5 +/- 0.2 ng/ml to 1.1 +/- 0.1 ng/ml (mean +/- SEM) (p = 0.05), cisapride lowered the peak concentration to 1.3 +/- 0.1 ng/ml (p = 0.14).",Effect of cisapride and metoclopramide on digoxin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),[ng] / [ml],1.3,131949,DB01233,Metoclopramide
,3582418,time required to reach the peak concentration,"Metoclopramide prolonged the time required to reach the peak concentration of digoxin from 2 hr to 2.7 hr (p = 0.17), cisapride did not.",Effect of cisapride and metoclopramide on digoxin bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),h,2,131950,DB01233,Metoclopramide
,3582418,time required to reach the peak concentration,"Metoclopramide prolonged the time required to reach the peak concentration of digoxin from 2 hr to 2.7 hr (p = 0.17), cisapride did not.",Effect of cisapride and metoclopramide on digoxin bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),h,2.7,131951,DB01233,Metoclopramide
,3582418,AUC0-12,"Digoxin AUC0-12 (743 +/- 79 ng/ml.min) was reduced by 12% on coadministration of cisapride (653 +/- 38 ng/ml.min, p = 0.22) and by 19% on coadministration of metoclopramide (605 +/- 34 ng/ml.min, p = 0.06).",Effect of cisapride and metoclopramide on digoxin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),[ng] / [min·ml],743,131952,DB01233,Metoclopramide
,3582418,AUC0-12,"Digoxin AUC0-12 (743 +/- 79 ng/ml.min) was reduced by 12% on coadministration of cisapride (653 +/- 38 ng/ml.min, p = 0.22) and by 19% on coadministration of metoclopramide (605 +/- 34 ng/ml.min, p = 0.06).",Effect of cisapride and metoclopramide on digoxin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),[ng] / [min·ml],653,131953,DB01233,Metoclopramide
,3582418,AUC0-12,"Digoxin AUC0-12 (743 +/- 79 ng/ml.min) was reduced by 12% on coadministration of cisapride (653 +/- 38 ng/ml.min, p = 0.22) and by 19% on coadministration of metoclopramide (605 +/- 34 ng/ml.min, p = 0.06).",Effect of cisapride and metoclopramide on digoxin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),[ng] / [min·ml],605,131954,DB01233,Metoclopramide
,2049236,clearance,"As a consequence of a 50% lower clearance (0.16 +/- 0.07 vs 0.34 +/- 0.09 l h-1 kg-1, plasma drug concentrations and the half-life of metoclopramide were greater in patients following both routes of drug administration.",Pharmacokinetics of metoclopramide in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049236/),[l] / [h·kg],0.16,134569,DB01233,Metoclopramide
,2049236,clearance,"As a consequence of a 50% lower clearance (0.16 +/- 0.07 vs 0.34 +/- 0.09 l h-1 kg-1, plasma drug concentrations and the half-life of metoclopramide were greater in patients following both routes of drug administration.",Pharmacokinetics of metoclopramide in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049236/),[l] / [h·kg],0.34,134570,DB01233,Metoclopramide
,2049236,Volume of distribution,Volume of distribution (3.1 +/- 0.8 vs 3.4 +/- 1.2 l kg-1) and absolute bioavailability (79 +/- 19 vs 84 +/- 15%) were similar in the two groups.,Pharmacokinetics of metoclopramide in patients with liver cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049236/),[l] / [kg],3.1,134571,DB01233,Metoclopramide
,2049236,Volume of distribution,Volume of distribution (3.1 +/- 0.8 vs 3.4 +/- 1.2 l kg-1) and absolute bioavailability (79 +/- 19 vs 84 +/- 15%) were similar in the two groups.,Pharmacokinetics of metoclopramide in patients with liver cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049236/),[l] / [kg],3.4,134572,DB01233,Metoclopramide
,2049236,absolute bioavailability,Volume of distribution (3.1 +/- 0.8 vs 3.4 +/- 1.2 l kg-1) and absolute bioavailability (79 +/- 19 vs 84 +/- 15%) were similar in the two groups.,Pharmacokinetics of metoclopramide in patients with liver cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049236/),%,79,134573,DB01233,Metoclopramide
,2049236,absolute bioavailability,Volume of distribution (3.1 +/- 0.8 vs 3.4 +/- 1.2 l kg-1) and absolute bioavailability (79 +/- 19 vs 84 +/- 15%) were similar in the two groups.,Pharmacokinetics of metoclopramide in patients with liver cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049236/),%,84,134574,DB01233,Metoclopramide
,3663273,oral bioavailability,"In contrast, the median oral bioavailability was considerably higher in patients with cirrhosis of the liver (82%) than in patients with normal liver function (60%).",Absolute bioavailability of metoclopramide given orally or by enema in patients with normal liver function or with cirrhosis of the liver. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663273/),%,82,139070,DB01233,Metoclopramide
,3663273,oral bioavailability,"In contrast, the median oral bioavailability was considerably higher in patients with cirrhosis of the liver (82%) than in patients with normal liver function (60%).",Absolute bioavailability of metoclopramide given orally or by enema in patients with normal liver function or with cirrhosis of the liver. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663273/),%,60,139071,DB01233,Metoclopramide
,9181602,bioavailable,The intramuscular administration of metoclopramide was also about 100% bioavailable compared to the intravenous route of administration.,"Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, sensamide and neu-sensamide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181602/),%,100,140484,DB01233,Metoclopramide
,31669384,first-order absorption rate (ka),"Population estimates were first-order absorption rate (ka) of 0.08 h - 1, fraction of dose absorbed by first-order (Fr) of 32.60%, duration of the zero-order absorption (Tk0) of 0.88 h with latency time (Tlag) of 0.47 h, volume of distribution of 230 l and clearance of 46.80 l h - 1.",Population pharmacokinetics of orally administrated bromopride: Focus on the absorption process. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31669384/),-·1·h,0.08,140491,DB01233,Metoclopramide
,31669384,duration of the zero-order absorption (Tk0),"Population estimates were first-order absorption rate (ka) of 0.08 h - 1, fraction of dose absorbed by first-order (Fr) of 32.60%, duration of the zero-order absorption (Tk0) of 0.88 h with latency time (Tlag) of 0.47 h, volume of distribution of 230 l and clearance of 46.80 l h - 1.",Population pharmacokinetics of orally administrated bromopride: Focus on the absorption process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31669384/),h,0.88,140492,DB01233,Metoclopramide
,31669384,latency time (Tlag),"Population estimates were first-order absorption rate (ka) of 0.08 h - 1, fraction of dose absorbed by first-order (Fr) of 32.60%, duration of the zero-order absorption (Tk0) of 0.88 h with latency time (Tlag) of 0.47 h, volume of distribution of 230 l and clearance of 46.80 l h - 1.",Population pharmacokinetics of orally administrated bromopride: Focus on the absorption process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31669384/),h,0.47,140493,DB01233,Metoclopramide
,31669384,volume of distribution,"Population estimates were first-order absorption rate (ka) of 0.08 h - 1, fraction of dose absorbed by first-order (Fr) of 32.60%, duration of the zero-order absorption (Tk0) of 0.88 h with latency time (Tlag) of 0.47 h, volume of distribution of 230 l and clearance of 46.80 l h - 1.",Population pharmacokinetics of orally administrated bromopride: Focus on the absorption process. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31669384/),l,230,140494,DB01233,Metoclopramide
,31669384,clearance,"Population estimates were first-order absorption rate (ka) of 0.08 h - 1, fraction of dose absorbed by first-order (Fr) of 32.60%, duration of the zero-order absorption (Tk0) of 0.88 h with latency time (Tlag) of 0.47 h, volume of distribution of 230 l and clearance of 46.80 l h - 1.",Population pharmacokinetics of orally administrated bromopride: Focus on the absorption process. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31669384/),-·1·h·l,46.80,140495,DB01233,Metoclopramide
,2744665,limit of detection,The limit of detection in serum samples was 2 ng/ml.,An automated high-performance liquid chromatographic trace enrichment method for the determination of metoclopramide in serum and its application to a bioequivalence human volunteer study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2744665/),[ng] / [ml],2,141225,DB01233,Metoclopramide
,2840652,sustained plasma concentration,From these values were calculated the individual loading and maintenance dosages required to obtain the sustained plasma concentration of 0.85 mg/l reported in the literature as being correlated with a good antiemetic effectiveness.,[Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840652/),[mg] / [l],0.85,143515,DB01233,Metoclopramide
,2840652,plasma concentration,The mean plasma concentration in the 10 patients studied was 0.84 +/- 0.19 mg/l with doses which varied considerably owing to marked scattering of pharmacokinetic parameters.,[Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840652/),[mg] / [l],0.84,143516,DB01233,Metoclopramide
,34148244,t1/2z,"All trazpiroben doses were rapidly absorbed and eliminated (t1/2z 4-5 hours), and D2 /D3 receptor target engagement confirmed by increased serum prolactin (peaking at trazpiroben 25 mg).","Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34148244/),h,4-5,143701,DB01233,Metoclopramide
,34148244,volume,"No effect on gastric emptying was demonstrated with trazpiroben or metoclopramide (P > 0.05), although benefits in volume-to-fullness were seen at trazpiroben 5 mg (P > 0.05) and 25 mg (88.5 vs -26.3 mL; P = 0.019), and nonsignificant numerical aggregate symptom score improvements were observed with trazpiroben 25 mg vs placebo (P = 0.182).","Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34148244/),m,88.5,143702,DB01233,Metoclopramide
,34148244,volume,"No effect on gastric emptying was demonstrated with trazpiroben or metoclopramide (P > 0.05), although benefits in volume-to-fullness were seen at trazpiroben 5 mg (P > 0.05) and 25 mg (88.5 vs -26.3 mL; P = 0.019), and nonsignificant numerical aggregate symptom score improvements were observed with trazpiroben 25 mg vs placebo (P = 0.182).","Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34148244/),m,26.,143703,DB01233,Metoclopramide
,6710558,retention time,The retention time for metoclopramide was 4.7 min.,"High-pressure liquid chromatographic method for determination of metoclopramide in serum, urine, and saliva, with a pharmacokinetic study in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710558/),min,4.7,146706,DB01233,Metoclopramide
,6710558,Recovery,Recovery was in the range of 93-110% for serum and 94-103% for urine.,"High-pressure liquid chromatographic method for determination of metoclopramide in serum, urine, and saliva, with a pharmacokinetic study in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710558/),%,93-110,146707,DB01233,Metoclopramide
,6710558,Recovery,Recovery was in the range of 93-110% for serum and 94-103% for urine.,"High-pressure liquid chromatographic method for determination of metoclopramide in serum, urine, and saliva, with a pharmacokinetic study in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710558/),%,94-103,146708,DB01233,Metoclopramide
,3580026,AUC,"Although peak plasma metoclopramide concentrations were lower, and occurred later after capsule treatment than after solution, analysis of the area under the plasma concentration-time curve (AUC) values for the two formulations demonstrated that the products were equivalent in terms of the extent of absorption, with the mean AUC value (0-30 h) for the capsule 943.7 ng/h/ml and that for the solution 896.2 ng/h/ml.",Bioavailability of controlled-release metoclopramide. 1st communication: single dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580026/),[ng] / [h·ml],943.7,147518,DB01233,Metoclopramide
,3580026,AUC,"Although peak plasma metoclopramide concentrations were lower, and occurred later after capsule treatment than after solution, analysis of the area under the plasma concentration-time curve (AUC) values for the two formulations demonstrated that the products were equivalent in terms of the extent of absorption, with the mean AUC value (0-30 h) for the capsule 943.7 ng/h/ml and that for the solution 896.2 ng/h/ml.",Bioavailability of controlled-release metoclopramide. 1st communication: single dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580026/),[ng] / [h·ml],896.2,147519,DB01233,Metoclopramide
,7497581,AUC (AUC,"Specifically, metoclopramide had little effect on the etoposide absorption profile and did not significantly alter the AUC (AUC with etoposide alone, 68.4 +/- 20.3 micrograms ml-1 h, versus 74.3 +/- 25.9 micrograms ml-1 h with metoclopramide), suggesting that in most patients the drug is already emptied rapidly from the stomach.",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],68.4,148763,DB01233,Metoclopramide
,7497581,AUC (AUC,"Specifically, metoclopramide had little effect on the etoposide absorption profile and did not significantly alter the AUC (AUC with etoposide alone, 68.4 +/- 20.3 micrograms ml-1 h, versus 74.3 +/- 25.9 micrograms ml-1 h with metoclopramide), suggesting that in most patients the drug is already emptied rapidly from the stomach.",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],74.3,148764,DB01233,Metoclopramide
,7497581,time of maximal concentration tmax,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),h,1.1,148765,DB01233,Metoclopramide
,7497581,time of maximal concentration tmax,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),h,3.5,148766,DB01233,Metoclopramide
,7497581,AUC,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],78.3,148767,DB01233,Metoclopramide
,7497581,AUC,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],88.1,148768,DB01233,Metoclopramide
,3544377,maximum blood concentration,Coadministration of cyclosporine with metoclopramide resulted in a significant increase in mean maximum blood concentration (567 ng/ml versus 388 ng/ml) and mean area under the blood-concentration-versus-time curve (4120 ng X hr/ml versus 3370 ng X hr/ml); and a significant decrease in mean time to reach maximum concentration.,The effect of oral metoclopramide on the absorption of cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3544377/),[ng] / [ml],567,149318,DB01233,Metoclopramide
,3544377,maximum blood concentration,Coadministration of cyclosporine with metoclopramide resulted in a significant increase in mean maximum blood concentration (567 ng/ml versus 388 ng/ml) and mean area under the blood-concentration-versus-time curve (4120 ng X hr/ml versus 3370 ng X hr/ml); and a significant decrease in mean time to reach maximum concentration.,The effect of oral metoclopramide on the absorption of cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3544377/),[ng] / [ml],388,149319,DB01233,Metoclopramide
,3544377,area under the blood-concentration-versus-time curve,Coadministration of cyclosporine with metoclopramide resulted in a significant increase in mean maximum blood concentration (567 ng/ml versus 388 ng/ml) and mean area under the blood-concentration-versus-time curve (4120 ng X hr/ml versus 3370 ng X hr/ml); and a significant decrease in mean time to reach maximum concentration.,The effect of oral metoclopramide on the absorption of cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3544377/),[h·ng] / [ml],4120,149320,DB01233,Metoclopramide
,3544377,area under the blood-concentration-versus-time curve,Coadministration of cyclosporine with metoclopramide resulted in a significant increase in mean maximum blood concentration (567 ng/ml versus 388 ng/ml) and mean area under the blood-concentration-versus-time curve (4120 ng X hr/ml versus 3370 ng X hr/ml); and a significant decrease in mean time to reach maximum concentration.,The effect of oral metoclopramide on the absorption of cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3544377/),[h·ng] / [ml],3370,149321,DB01233,Metoclopramide
,2340846,f,"Mean f in the patients was 0.28, which was significantly higher than in 12 normal subjects (0.14).",Absolute bioavailability of pirenzepine in intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340846/),,0.28,150118,DB01233,Metoclopramide
,2340846,f,"Mean f in the patients was 0.28, which was significantly higher than in 12 normal subjects (0.14).",Absolute bioavailability of pirenzepine in intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340846/),,0.14,150119,DB01233,Metoclopramide
,21643856,flow rate,"The instrument used was a Shimadzu LC-10Av chromatograph and flow rate was 1.5 ml min(-1), with a LaChrom L-7400 UV detector set at 230 nm.",Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21643856/),[ml] / [min],1.5,151293,DB01233,Metoclopramide
,16959453,T(max),"The application of a nasal spray (NS) solution containing 0.5% sodium cholate resulted in a significant improvement (P<0.05) in both the rate and extent of absorption of MCP HCl where the T(max) achieved was 23.3min as compared to 50min in case of the oral solution while the area under the serum concentration-time curve (AUC(0-infinity)) were 506.1, 434.9 and 278.7microg/mlmin for IV, NS and oral solutions, respectively.",Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16959453/),min,23.3,151886,DB01233,Metoclopramide
,16959453,T(max),"The application of a nasal spray (NS) solution containing 0.5% sodium cholate resulted in a significant improvement (P<0.05) in both the rate and extent of absorption of MCP HCl where the T(max) achieved was 23.3min as compared to 50min in case of the oral solution while the area under the serum concentration-time curve (AUC(0-infinity)) were 506.1, 434.9 and 278.7microg/mlmin for IV, NS and oral solutions, respectively.",Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16959453/),min,50,151887,DB01233,Metoclopramide
,16959453,area under the serum concentration-time curve (AUC(0-infinity)),"The application of a nasal spray (NS) solution containing 0.5% sodium cholate resulted in a significant improvement (P<0.05) in both the rate and extent of absorption of MCP HCl where the T(max) achieved was 23.3min as compared to 50min in case of the oral solution while the area under the serum concentration-time curve (AUC(0-infinity)) were 506.1, 434.9 and 278.7microg/mlmin for IV, NS and oral solutions, respectively.",Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16959453/),[μg] / [mlmin],506.1,151888,DB01233,Metoclopramide
,16959453,area under the serum concentration-time curve (AUC(0-infinity)),"The application of a nasal spray (NS) solution containing 0.5% sodium cholate resulted in a significant improvement (P<0.05) in both the rate and extent of absorption of MCP HCl where the T(max) achieved was 23.3min as compared to 50min in case of the oral solution while the area under the serum concentration-time curve (AUC(0-infinity)) were 506.1, 434.9 and 278.7microg/mlmin for IV, NS and oral solutions, respectively.",Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16959453/),[μg] / [mlmin],434.9,151889,DB01233,Metoclopramide
,16959453,area under the serum concentration-time curve (AUC(0-infinity)),"The application of a nasal spray (NS) solution containing 0.5% sodium cholate resulted in a significant improvement (P<0.05) in both the rate and extent of absorption of MCP HCl where the T(max) achieved was 23.3min as compared to 50min in case of the oral solution while the area under the serum concentration-time curve (AUC(0-infinity)) were 506.1, 434.9 and 278.7microg/mlmin for IV, NS and oral solutions, respectively.",Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16959453/),[μg] / [mlmin],278.7,151890,DB01233,Metoclopramide
,16959453,absolute bioavailabilities,"These values corresponded to absolute bioavailabilities of 87.21 and 55.61% for the NS and oral solutions, respectively.",Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16959453/),%,87.21,151891,DB01233,Metoclopramide
,16959453,absolute bioavailabilities,"These values corresponded to absolute bioavailabilities of 87.21 and 55.61% for the NS and oral solutions, respectively.",Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16959453/),%,55.61,151892,DB01233,Metoclopramide
,6508977,half-life,In these six patients plasma metoclopramide half-life was 5.9 +/- 0.4 h (mean +/- s.e. mean) and plasma clearance was 25.4 +/- 4.8 l/h (mean +/- s.e. mean).,Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508977/),h,5.9,153035,DB01233,Metoclopramide
,6508977,plasma clearance,In these six patients plasma metoclopramide half-life was 5.9 +/- 0.4 h (mean +/- s.e. mean) and plasma clearance was 25.4 +/- 4.8 l/h (mean +/- s.e. mean).,Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508977/),[l] / [h],25.4,153036,DB01233,Metoclopramide
,2050180,elimination half-life,"The elimination half-life was significantly longer in patients (11.4 h and 9.9 h in those with and without ascites, respectively, vs 6.4 h in controls).",Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050180/),h,11.4,155041,DB01233,Metoclopramide
,2050180,elimination half-life,"The elimination half-life was significantly longer in patients (11.4 h and 9.9 h in those with and without ascites, respectively, vs 6.4 h in controls).",Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050180/),h,9.9,155042,DB01233,Metoclopramide
,2050180,elimination half-life,"The elimination half-life was significantly longer in patients (11.4 h and 9.9 h in those with and without ascites, respectively, vs 6.4 h in controls).",Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050180/),h,6.4,155043,DB01233,Metoclopramide
,2050180,Total plasma clearance,Total plasma clearance was significantly lower in patients (0.29 and 0.36 l.kg-1.h-1 vs 0.52 l.kg-1.h-1 in controls).,Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050180/),[l] / [h·kg],0.29,155044,DB01233,Metoclopramide
,2050180,Total plasma clearance,Total plasma clearance was significantly lower in patients (0.29 and 0.36 l.kg-1.h-1 vs 0.52 l.kg-1.h-1 in controls).,Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050180/),[l] / [h·kg],0.36,155045,DB01233,Metoclopramide
,2050180,Total plasma clearance,Total plasma clearance was significantly lower in patients (0.29 and 0.36 l.kg-1.h-1 vs 0.52 l.kg-1.h-1 in controls).,Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050180/),[l] / [h·kg],0.52,155046,DB01233,Metoclopramide
,16028097,time to equilibrium,"The time to equilibrium was established to be within 5 h, and the mean unbound fraction of MS-275 (f (u)) over a presumed therapeutic concentration range in healthy volunteer human plasma was 0.188 +/- 0.0075 as compared to 0.168 +/- 0.0144 in cancer patients.","Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028097/),h,5,158186,DB01233,Metoclopramide
,16028097,unbound fraction of MS-275 (f (u)),"The time to equilibrium was established to be within 5 h, and the mean unbound fraction of MS-275 (f (u)) over a presumed therapeutic concentration range in healthy volunteer human plasma was 0.188 +/- 0.0075 as compared to 0.168 +/- 0.0144 in cancer patients.","Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028097/),,0.188,158187,DB01233,Metoclopramide
,16028097,unbound fraction of MS-275 (f (u)),"The time to equilibrium was established to be within 5 h, and the mean unbound fraction of MS-275 (f (u)) over a presumed therapeutic concentration range in healthy volunteer human plasma was 0.188 +/- 0.0075 as compared to 0.168 +/- 0.0144 in cancer patients.","Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028097/),,0.168,158188,DB01233,Metoclopramide
,16028097,f (u),"Among 19 tested drugs, a slightly increased f (u) was observed in the presence of only ibuprofen (f (u), 0.236 +/- 0.001) and metoclopramide (f (u), 0.270 +/- 0.042), suggesting weakly competitive displacement from protein-binding sites (P < 0.01).","Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028097/),,0.236,158189,DB01233,Metoclopramide
,16028097,f (u),"Among 19 tested drugs, a slightly increased f (u) was observed in the presence of only ibuprofen (f (u), 0.236 +/- 0.001) and metoclopramide (f (u), 0.270 +/- 0.042), suggesting weakly competitive displacement from protein-binding sites (P < 0.01).","Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028097/),,0.270,158190,DB01233,Metoclopramide
,16867768,limit of detection,The limit of detection (at 310 nm) was 7 ng/ml and no interference from endogenous plasma components or from any drugs commonly used in the treatment of cancer was observed.,The determination of metoclopramide in plasma by reversed-phase ion-pair high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867768/),[ng] / [ml],7,161723,DB01233,Metoclopramide
,7889009,maximum concentrations,Mean maximum concentrations were 1512 ng/ml; mean trough levels for second and subsequent doses were 615 ng/ml.,Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7889009/),[ng] / [ml],1512,164421,DB01233,Metoclopramide
,7889009,trough levels,Mean maximum concentrations were 1512 ng/ml; mean trough levels for second and subsequent doses were 615 ng/ml.,Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7889009/),[ng] / [ml],615,164422,DB01233,Metoclopramide
,7286058,terminal half-life,Plasma concentration-time data following i. v. administration in each subject were found to fit a two compartment model with a mean terminal half-life of 4.55 h +/- 0.80 h and a mean distribution half-time of 0.35 h +/- 0.09 h.,Single-dose pharmacokinetics of metoclopramide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286058/),h,4.55,164495,DB01233,Metoclopramide
,7286058,distribution half-time,Plasma concentration-time data following i. v. administration in each subject were found to fit a two compartment model with a mean terminal half-life of 4.55 h +/- 0.80 h and a mean distribution half-time of 0.35 h +/- 0.09 h.,Single-dose pharmacokinetics of metoclopramide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286058/),h,0.35,164496,DB01233,Metoclopramide
,7286058,Volumes of distribution,"Volumes of distribution were high (3.43 +/- 1.181 . kg-1), and clearances (0.53 +/- 0.191 . kg-1 h-1) approached liver plasma flow.",Single-dose pharmacokinetics of metoclopramide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286058/),1/[kg],3.43,164497,DB01233,Metoclopramide
,7286058,clearances,"Volumes of distribution were high (3.43 +/- 1.181 . kg-1), and clearances (0.53 +/- 0.191 . kg-1 h-1) approached liver plasma flow.",Single-dose pharmacokinetics of metoclopramide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286058/),1/[h·kg],0.53,164498,DB01233,Metoclopramide
,7286058,terminal half-life,The terminal half-life was 5.17 h +/- 0.98 h.,Single-dose pharmacokinetics of metoclopramide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286058/),h,5.17,164499,DB01233,Metoclopramide
,7286058,mean time,Oral absorption was rapid with peak plasma concentrations being reached at a mean time of 0.93 h.,Single-dose pharmacokinetics of metoclopramide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286058/),h,0.93,164500,DB01233,Metoclopramide
,7286058,bioavailability,"A mean bioavailability of 0.77 was calculated for the six subjects, and it was postulated that this incomplete availability is due to a first-pass effect.",Single-dose pharmacokinetics of metoclopramide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286058/),,0.77,164501,DB01233,Metoclopramide
,24277185,limit of sensitivity,The method is highly reproducible and has a limit of sensitivity of 2.5 ng/ml from a 2.0 ml serum sample.,High pressure liquid chromatographic analysis of metoclopramide in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277185/),[ng] / [ml],2.5,164725,DB01233,Metoclopramide
,17920822,absolute bioavailability,The bioavailability study in rabbits revealed that the absolute bioavailability of MCP HCl was significantly increased from 51.7% in case of the oral drug solution to 69.1% in case of the nasal in situ gel.,Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920822/),%,51.7,164891,DB01233,Metoclopramide
,17920822,absolute bioavailability,The bioavailability study in rabbits revealed that the absolute bioavailability of MCP HCl was significantly increased from 51.7% in case of the oral drug solution to 69.1% in case of the nasal in situ gel.,Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920822/),%,69.1,164892,DB01233,Metoclopramide
,6540582,bioavailability,An approximate value of 71% was obtained for the bioavailability of metoclopramide of Gastronerton retard capsules.,[Bioavailability of metoclopramide in a sustained-release preparation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540582/),%,71,166276,DB01233,Metoclopramide
,7741790,relative bioavailability,The relative bioavailability (mean and nonparametric 95% confidence interval) with respect to a reference preparation was 0.95 (95% CI 0.88-1.02) for AUC and 0.92 (95% CI 0.79-1.07) for Cmax.,[The bioequivalence of metoclopramide in two tablet formulations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741790/),,0,167836,DB01233,Metoclopramide
,15470533,peak plasma concentrations Cmax,"In the two periods of treatments, the mean peak plasma concentrations Cmax were 44 ng/ml (metoclopramide alone) and 49.2 ng/ml (metoclopramide and ranitidine).",Pharmacokinetic interaction study between ranitidine and metoclopramide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),[ng] / [ml],44,168884,DB01233,Metoclopramide
,15470533,peak plasma concentrations Cmax,"In the two periods of treatments, the mean peak plasma concentrations Cmax were 44 ng/ml (metoclopramide alone) and 49.2 ng/ml (metoclopramide and ranitidine).",Pharmacokinetic interaction study between ranitidine and metoclopramide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),[ng] / [ml],49.2,168885,DB01233,Metoclopramide
,15470533,"time taken to reach the peak, Tmax","The time taken to reach the peak, Tmax, was 1.15 hrs, and 1.21 hrs, respectively.",Pharmacokinetic interaction study between ranitidine and metoclopramide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),h,1.15,168886,DB01233,Metoclopramide
,15470533,"time taken to reach the peak, Tmax","The time taken to reach the peak, Tmax, was 1.15 hrs, and 1.21 hrs, respectively.",Pharmacokinetic interaction study between ranitidine and metoclopramide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),h,1.21,168887,DB01233,Metoclopramide
,15470533,total areas under the curve (AUC),"The total areas under the curve (AUC) was 314.3 ng.hr/ml and 354.06 ng.hr/ml, respectively.",Pharmacokinetic interaction study between ranitidine and metoclopramide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),[h·ng] / [ml],314.3,168888,DB01233,Metoclopramide
,15470533,total areas under the curve (AUC),"The total areas under the curve (AUC) was 314.3 ng.hr/ml and 354.06 ng.hr/ml, respectively.",Pharmacokinetic interaction study between ranitidine and metoclopramide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),[h·ng] / [ml],354.06,168889,DB01233,Metoclopramide
,15470533,half-life (T 1/2),The half-life (T 1/2) was 5.6 hr and 6.7 hr.,Pharmacokinetic interaction study between ranitidine and metoclopramide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),h,5.6,168890,DB01233,Metoclopramide
,15470533,half-life (T 1/2),The half-life (T 1/2) was 5.6 hr and 6.7 hr.,Pharmacokinetic interaction study between ranitidine and metoclopramide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),h,6.7,168891,DB01233,Metoclopramide
,20949310,kg1,"The final model has two gastric emptying rate constant parameters: kg1 (1.30 h(-1), RSE=53.84%, T1/2=0.53 h) for the intolerant group before prokinetic therapy and kg2 (27.8 h(-1), RSE=59.35%, T1/2=0.025 h) for both the intolerant group after prokinetic therapy and the tolerant group.",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),1/[h],1.30,177285,DB01233,Metoclopramide
,20949310,T1/2,"The final model has two gastric emptying rate constant parameters: kg1 (1.30 h(-1), RSE=53.84%, T1/2=0.53 h) for the intolerant group before prokinetic therapy and kg2 (27.8 h(-1), RSE=59.35%, T1/2=0.025 h) for both the intolerant group after prokinetic therapy and the tolerant group.",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),h,0.53,177286,DB01233,Metoclopramide
,20949310,kg2,"The final model has two gastric emptying rate constant parameters: kg1 (1.30 h(-1), RSE=53.84%, T1/2=0.53 h) for the intolerant group before prokinetic therapy and kg2 (27.8 h(-1), RSE=59.35%, T1/2=0.025 h) for both the intolerant group after prokinetic therapy and the tolerant group.",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),1/[h],27.8,177287,DB01233,Metoclopramide
,20949310,T1/2,"The final model has two gastric emptying rate constant parameters: kg1 (1.30 h(-1), RSE=53.84%, T1/2=0.53 h) for the intolerant group before prokinetic therapy and kg2 (27.8 h(-1), RSE=59.35%, T1/2=0.025 h) for both the intolerant group after prokinetic therapy and the tolerant group.",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),h,0.025,177288,DB01233,Metoclopramide
,20949310,ka,"Other parameters and estimates (RSE) in the model were ka=5.12 h(-1) (28.13%), CL=13.0 L/h (19.62%), CLD=22.6 L/h (19.78%), V1=63.8 L (12.79%) and V2=69 L (38.70%).",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),1/[h],5.12,177289,DB01233,Metoclopramide
,20949310,CL,"Other parameters and estimates (RSE) in the model were ka=5.12 h(-1) (28.13%), CL=13.0 L/h (19.62%), CLD=22.6 L/h (19.78%), V1=63.8 L (12.79%) and V2=69 L (38.70%).",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),[l] / [h],13.0,177290,DB01233,Metoclopramide
,20949310,CLD,"Other parameters and estimates (RSE) in the model were ka=5.12 h(-1) (28.13%), CL=13.0 L/h (19.62%), CLD=22.6 L/h (19.78%), V1=63.8 L (12.79%) and V2=69 L (38.70%).",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),[l] / [h],22.6,177291,DB01233,Metoclopramide
,20949310,V1,"Other parameters and estimates (RSE) in the model were ka=5.12 h(-1) (28.13%), CL=13.0 L/h (19.62%), CLD=22.6 L/h (19.78%), V1=63.8 L (12.79%) and V2=69 L (38.70%).",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),l,63.8,177292,DB01233,Metoclopramide
,20949310,V2,"Other parameters and estimates (RSE) in the model were ka=5.12 h(-1) (28.13%), CL=13.0 L/h (19.62%), CLD=22.6 L/h (19.78%), V1=63.8 L (12.79%) and V2=69 L (38.70%).",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),l,69,177293,DB01233,Metoclopramide
,6683522,bioavailability,The studies led to the following result: The bioavailability of the substance bromopride amounts to about 70% and increases after multiple administration to about 90%.,[Pharmacokinetics and absolute bioavailability of bromopride from various pharmaceutical formulations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683522/),%,70,177323,DB01233,Metoclopramide
,6683522,bioavailability,The studies led to the following result: The bioavailability of the substance bromopride amounts to about 70% and increases after multiple administration to about 90%.,[Pharmacokinetics and absolute bioavailability of bromopride from various pharmaceutical formulations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683522/),%,90,177324,DB01233,Metoclopramide
,25199779,relative bioavailability,Posaconazole relative bioavailability was 55% lower in patients who received posaconazole than in healthy volunteers.,Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25199779/),%,55,177817,DB01233,Metoclopramide
,29853808,AUCliver,AUCliver was lower using the pharmacologic dose (42.9 ± 13.8 SUV·min) compared with the tracer dose (210.0 ± 32.4 SUV·min).,Positron Emission Tomography Imaging Reveals an Importance of Saturable Liver Uptake Transport for the Pharmacokinetics of Metoclopramide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29853808/),min·suv,42.9,178586,DB01233,Metoclopramide
,29853808,AUCliver,AUCliver was lower using the pharmacologic dose (42.9 ± 13.8 SUV·min) compared with the tracer dose (210.0 ± 32.4 SUV·min).,Positron Emission Tomography Imaging Reveals an Importance of Saturable Liver Uptake Transport for the Pharmacokinetics of Metoclopramide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29853808/),min·suv,210.0,178587,DB01233,Metoclopramide
,8207687,bioavailability,"Moreover, the bioavailability of the sulfone metabolite was very poor (2.5-4%) following separate oral administration of ML-1035, 2, and 3.",Determination of bioavailability and systemically available fractions of drugs undergoing reversible metabolism: application to 4-amino-5-chloro-2-[2-(methylsulfinyl)ethoxy]-N-[2- (diethylamino)ethyl]benzamide and its sulfide and sulfone metabolites in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8207687/),%,2.5-4,179197,DB01233,Metoclopramide
,3667781,detection limit,"The detector response is linear from 25 to 10,000 ng/ml, and the detection limit is 3 ng/ml for alizapride and 10 ng/ml for metoclopramide.",Liquid chromatographic analysis of alizapride and metoclopramide in human plasma and urine using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667781/),[ng] / [ml],3,185208,DB01233,Metoclopramide
,3667781,detection limit,"The detector response is linear from 25 to 10,000 ng/ml, and the detection limit is 3 ng/ml for alizapride and 10 ng/ml for metoclopramide.",Liquid chromatographic analysis of alizapride and metoclopramide in human plasma and urine using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667781/),[ng] / [ml],10,185209,DB01233,Metoclopramide
,8112368,Cmax,The mean Cmax values were significantly greater for the didanosine single agent (2.04 micrograms.,Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112368/),μg,2.04,186193,DB01233,Metoclopramide
,8112368,t1/2,"The t1/2 in males was significantly greater than in females for the didanosine (1.75 vs 1.12 h, respectively) and didanosine with metoclopramide treatments (1.74 vs 1.20 h, respectively).",Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112368/),h,1.75,186194,DB01233,Metoclopramide
,8112368,t1/2,"The t1/2 in males was significantly greater than in females for the didanosine (1.75 vs 1.12 h, respectively) and didanosine with metoclopramide treatments (1.74 vs 1.20 h, respectively).",Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112368/),h,1.12,186195,DB01233,Metoclopramide
,8112368,t1/2,"The t1/2 in males was significantly greater than in females for the didanosine (1.75 vs 1.12 h, respectively) and didanosine with metoclopramide treatments (1.74 vs 1.20 h, respectively).",Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112368/),h,1.74,186196,DB01233,Metoclopramide
,8112368,t1/2,"The t1/2 in males was significantly greater than in females for the didanosine (1.75 vs 1.12 h, respectively) and didanosine with metoclopramide treatments (1.74 vs 1.20 h, respectively).",Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112368/),h,1.20,186197,DB01233,Metoclopramide
,7400276,percentage recovery of,"The percentage recovery of drug from plasma ranges from 88% to virtually 100%, and the between-run variation in the assay is 4.3%.",Electron-capture gas chromatographic assay for metoclopramide in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400276/),%,88,188556,DB01233,Metoclopramide
,7400276,percentage recovery of,"The percentage recovery of drug from plasma ranges from 88% to virtually 100%, and the between-run variation in the assay is 4.3%.",Electron-capture gas chromatographic assay for metoclopramide in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400276/),%,100,188557,DB01233,Metoclopramide
,7400276,terminal half-life,"The resultant plasma concentration vs. time curve was biexponential, with a terminal half-life of 5.0 h, and a distribution half-time of 0.3 h.",Electron-capture gas chromatographic assay for metoclopramide in plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400276/),h,5.0,188558,DB01233,Metoclopramide
,7400276,distribution half-time,"The resultant plasma concentration vs. time curve was biexponential, with a terminal half-life of 5.0 h, and a distribution half-time of 0.3 h.",Electron-capture gas chromatographic assay for metoclopramide in plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400276/),h,0.3,188559,DB01233,Metoclopramide
,3667782,recoveries,"The method is precise, selective and sensitive: the mean recoveries of metoclopramide from plasma, urine and bile were 74.4, 99.1 and 85.9%, respectively; the mean within- and between-run coefficients of variation were, respectively, 0.8 and 8.5% for plasma and 2.0 and 8.2% for urine at the drug concentration of 100 ng/ml, and 2.3 and 11.2% for bile at the concentration of 20 ng/ml; the lower detection limit was 2 ng/ml for 1 ml of each biological fluid.","Determination of metoclopramide and its glucuronide and sulphate conjugates in human biological fluids (plasma, urine and bile) by ion-pair high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667782/),%,74.4,190164,DB01233,Metoclopramide
,3667782,recoveries,"The method is precise, selective and sensitive: the mean recoveries of metoclopramide from plasma, urine and bile were 74.4, 99.1 and 85.9%, respectively; the mean within- and between-run coefficients of variation were, respectively, 0.8 and 8.5% for plasma and 2.0 and 8.2% for urine at the drug concentration of 100 ng/ml, and 2.3 and 11.2% for bile at the concentration of 20 ng/ml; the lower detection limit was 2 ng/ml for 1 ml of each biological fluid.","Determination of metoclopramide and its glucuronide and sulphate conjugates in human biological fluids (plasma, urine and bile) by ion-pair high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667782/),%,99.1,190165,DB01233,Metoclopramide
,3667782,recoveries,"The method is precise, selective and sensitive: the mean recoveries of metoclopramide from plasma, urine and bile were 74.4, 99.1 and 85.9%, respectively; the mean within- and between-run coefficients of variation were, respectively, 0.8 and 8.5% for plasma and 2.0 and 8.2% for urine at the drug concentration of 100 ng/ml, and 2.3 and 11.2% for bile at the concentration of 20 ng/ml; the lower detection limit was 2 ng/ml for 1 ml of each biological fluid.","Determination of metoclopramide and its glucuronide and sulphate conjugates in human biological fluids (plasma, urine and bile) by ion-pair high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667782/),%,85.9,190166,DB01233,Metoclopramide
,3667782,recoveries,"The method is precise, selective and sensitive: the mean recoveries of metoclopramide from plasma, urine and bile were 74.4, 99.1 and 85.9%, respectively; the mean within- and between-run coefficients of variation were, respectively, 0.8 and 8.5% for plasma and 2.0 and 8.2% for urine at the drug concentration of 100 ng/ml, and 2.3 and 11.2% for bile at the concentration of 20 ng/ml; the lower detection limit was 2 ng/ml for 1 ml of each biological fluid.","Determination of metoclopramide and its glucuronide and sulphate conjugates in human biological fluids (plasma, urine and bile) by ion-pair high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667782/),%,2.,190167,DB01233,Metoclopramide
,3667782,recoveries,"The method is precise, selective and sensitive: the mean recoveries of metoclopramide from plasma, urine and bile were 74.4, 99.1 and 85.9%, respectively; the mean within- and between-run coefficients of variation were, respectively, 0.8 and 8.5% for plasma and 2.0 and 8.2% for urine at the drug concentration of 100 ng/ml, and 2.3 and 11.2% for bile at the concentration of 20 ng/ml; the lower detection limit was 2 ng/ml for 1 ml of each biological fluid.","Determination of metoclopramide and its glucuronide and sulphate conjugates in human biological fluids (plasma, urine and bile) by ion-pair high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667782/),%,2,190168,DB01233,Metoclopramide
,999405,peak concentrations,"The peak concentrations in 3 dogs given 25, 50 or 100 mg/kg orally were 6.1, 15.6 and 23.9 mug/ml, respectively.",Pharmacokinetics of sulpiride after oral and intravenous administration in the rat and the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999405/),[μg] / [ml],6.1,191086,DB01233,Metoclopramide
,999405,peak concentrations,"The peak concentrations in 3 dogs given 25, 50 or 100 mg/kg orally were 6.1, 15.6 and 23.9 mug/ml, respectively.",Pharmacokinetics of sulpiride after oral and intravenous administration in the rat and the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999405/),[μg] / [ml],15.6,191087,DB01233,Metoclopramide
,999405,peak concentrations,"The peak concentrations in 3 dogs given 25, 50 or 100 mg/kg orally were 6.1, 15.6 and 23.9 mug/ml, respectively.",Pharmacokinetics of sulpiride after oral and intravenous administration in the rat and the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999405/),[μg] / [ml],23.9,191088,DB01233,Metoclopramide
,999405,half-life,"The half-life of sulpiride in dog plasma (1.6 -- 3.4 hr) is longer than that of metoclopramide, but in the rat there is little difference between the two compounds.",Pharmacokinetics of sulpiride after oral and intravenous administration in the rat and the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999405/),h,1,191089,DB01233,Metoclopramide
,999405,total apparent volumes of distribution,Both of the compounds have large total apparent volumes of distribution (1-2 1/kg) in the two species.,Pharmacokinetics of sulpiride after oral and intravenous administration in the rat and the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999405/),[1] / [kg],1-2,191090,DB01233,Metoclopramide
,20189472,recovery,"The recovery was 67.8-83.1%, and the limit of quantitation (LOQ) detection was 0.78 ng mL(-1) for metoclopramide.",Determination of metoclopramide in human plasma by LC-ESI-MS and its application to bioequivalance studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20189472/),%,67.8-83.1,193352,DB01233,Metoclopramide
,21665047,C(max),"Peak plasma concentrations were lower (C(max), 33.13 [7.25] vs 46.04 [17.27] ng/mL after the first dose [P < 0.05]; C(max,ss), 48.60 [8.52] vs 75.23 [21.27] ng/mL after the last dose [P < 0.05]) and occurred later (P < 0.05) with the modified-release formulation.","Comparison of the pharmacokinetics of a new 15-mg modified-release tablet formulation of metoclopramide versus a 10-mg immediate-release tablet: a single- and multiple-dose, randomized, open-label, parallel-group study in healthy Mexican male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665047/),[ng] / [ml],33.13,203881,DB01233,Metoclopramide
,21665047,C(max),"Peak plasma concentrations were lower (C(max), 33.13 [7.25] vs 46.04 [17.27] ng/mL after the first dose [P < 0.05]; C(max,ss), 48.60 [8.52] vs 75.23 [21.27] ng/mL after the last dose [P < 0.05]) and occurred later (P < 0.05) with the modified-release formulation.","Comparison of the pharmacokinetics of a new 15-mg modified-release tablet formulation of metoclopramide versus a 10-mg immediate-release tablet: a single- and multiple-dose, randomized, open-label, parallel-group study in healthy Mexican male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665047/),[ng] / [ml],46.04,203882,DB01233,Metoclopramide
,21665047,"C(max,ss)","Peak plasma concentrations were lower (C(max), 33.13 [7.25] vs 46.04 [17.27] ng/mL after the first dose [P < 0.05]; C(max,ss), 48.60 [8.52] vs 75.23 [21.27] ng/mL after the last dose [P < 0.05]) and occurred later (P < 0.05) with the modified-release formulation.","Comparison of the pharmacokinetics of a new 15-mg modified-release tablet formulation of metoclopramide versus a 10-mg immediate-release tablet: a single- and multiple-dose, randomized, open-label, parallel-group study in healthy Mexican male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665047/),[ng] / [ml],48.60,203883,DB01233,Metoclopramide
,21665047,"C(max,ss)","Peak plasma concentrations were lower (C(max), 33.13 [7.25] vs 46.04 [17.27] ng/mL after the first dose [P < 0.05]; C(max,ss), 48.60 [8.52] vs 75.23 [21.27] ng/mL after the last dose [P < 0.05]) and occurred later (P < 0.05) with the modified-release formulation.","Comparison of the pharmacokinetics of a new 15-mg modified-release tablet formulation of metoclopramide versus a 10-mg immediate-release tablet: a single- and multiple-dose, randomized, open-label, parallel-group study in healthy Mexican male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665047/),[ng] / [ml],75.23,203884,DB01233,Metoclopramide
,21665047,plasma concentrations (C(avgτ),"In terms of average plasma concentrations (C(avgτ), 20.98 [3.94] vs 23.38 [7.35] ng/mL after the first dose; C(avg,ss), 22.20 [5.64] vs 23.02 [7.77] ng/mL after the last dose), differences did not reach the level of statistical significance (P > 0.05).","Comparison of the pharmacokinetics of a new 15-mg modified-release tablet formulation of metoclopramide versus a 10-mg immediate-release tablet: a single- and multiple-dose, randomized, open-label, parallel-group study in healthy Mexican male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665047/),[ng] / [ml],20.98,203885,DB01233,Metoclopramide
,21665047,plasma concentrations (C(avgτ),"In terms of average plasma concentrations (C(avgτ), 20.98 [3.94] vs 23.38 [7.35] ng/mL after the first dose; C(avg,ss), 22.20 [5.64] vs 23.02 [7.77] ng/mL after the last dose), differences did not reach the level of statistical significance (P > 0.05).","Comparison of the pharmacokinetics of a new 15-mg modified-release tablet formulation of metoclopramide versus a 10-mg immediate-release tablet: a single- and multiple-dose, randomized, open-label, parallel-group study in healthy Mexican male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665047/),[ng] / [ml],23.38,203886,DB01233,Metoclopramide
,21665047,"C(avg,ss)","In terms of average plasma concentrations (C(avgτ), 20.98 [3.94] vs 23.38 [7.35] ng/mL after the first dose; C(avg,ss), 22.20 [5.64] vs 23.02 [7.77] ng/mL after the last dose), differences did not reach the level of statistical significance (P > 0.05).","Comparison of the pharmacokinetics of a new 15-mg modified-release tablet formulation of metoclopramide versus a 10-mg immediate-release tablet: a single- and multiple-dose, randomized, open-label, parallel-group study in healthy Mexican male volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665047/),[ng] / [ml],22.20,203887,DB01233,Metoclopramide
,21665047,"C(avg,ss)","In terms of average plasma concentrations (C(avgτ), 20.98 [3.94] vs 23.38 [7.35] ng/mL after the first dose; C(avg,ss), 22.20 [5.64] vs 23.02 [7.77] ng/mL after the last dose), differences did not reach the level of statistical significance (P > 0.05).","Comparison of the pharmacokinetics of a new 15-mg modified-release tablet formulation of metoclopramide versus a 10-mg immediate-release tablet: a single- and multiple-dose, randomized, open-label, parallel-group study in healthy Mexican male volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665047/),[ng] / [ml],23.02,203888,DB01233,Metoclopramide
,1573702,peak,Mean serum concentrations of metoclopramide following i.v. administration of 0.5 mg/kg declined rapidly from a peak of 277.5 ng/ml at 3 min post-dosing to 25 ng/ml at 90 min.,Pharmacokinetics of metoclopramide in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573702/),[ng] / [ml],277.5,211222,DB01233,Metoclopramide
,1573702,biological half-life,Mean parameters from analysis of the individual i.v. data gave a biological half-life of 0.62 h and a volume of distribution of the central compartment of 1.34 l/kg.,Pharmacokinetics of metoclopramide in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573702/),h,0.62,211223,DB01233,Metoclopramide
,1573702,volume of distribution of the central compartment,Mean parameters from analysis of the individual i.v. data gave a biological half-life of 0.62 h and a volume of distribution of the central compartment of 1.34 l/kg.,Pharmacokinetics of metoclopramide in goats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573702/),[l] / [kg],1.34,211224,DB01233,Metoclopramide
,1573702,biological half-life,The mean biological half-life was 1.04 h.,Pharmacokinetics of metoclopramide in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573702/),h,1.04,211225,DB01233,Metoclopramide
,1467455,half-life,After intravenous dosing ML-1035 was eliminated with a half-life of 1.45 +/- 0.49 h in males and 0.79 +/- 0.08 h in females.,Sex-differences in the disposition of substituted benzamides: pharmacokinetics of a gastroprokinetic agent (4-amino-5-chloro-2-[2- (methylsulfinyl) ethoxy]-N-[2-(diethylamino)ethyl] benzamide hydrochloride) (ML-1035) in male and female New Zealand white rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467455/),h,1.45,213538,DB01233,Metoclopramide
,1467455,half-life,After intravenous dosing ML-1035 was eliminated with a half-life of 1.45 +/- 0.49 h in males and 0.79 +/- 0.08 h in females.,Sex-differences in the disposition of substituted benzamides: pharmacokinetics of a gastroprokinetic agent (4-amino-5-chloro-2-[2- (methylsulfinyl) ethoxy]-N-[2-(diethylamino)ethyl] benzamide hydrochloride) (ML-1035) in male and female New Zealand white rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467455/),h,0.79,213539,DB01233,Metoclopramide
,1467455,Volume of distribution at steady-state,Volume of distribution at steady-state was 2.08 +/- 0.98 l kg-1 in males and 9.11 +/- 5.86 l kg-1 in females.,Sex-differences in the disposition of substituted benzamides: pharmacokinetics of a gastroprokinetic agent (4-amino-5-chloro-2-[2- (methylsulfinyl) ethoxy]-N-[2-(diethylamino)ethyl] benzamide hydrochloride) (ML-1035) in male and female New Zealand white rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467455/),[l] / [kg],2.08,213540,DB01233,Metoclopramide
,1467455,Volume of distribution at steady-state,Volume of distribution at steady-state was 2.08 +/- 0.98 l kg-1 in males and 9.11 +/- 5.86 l kg-1 in females.,Sex-differences in the disposition of substituted benzamides: pharmacokinetics of a gastroprokinetic agent (4-amino-5-chloro-2-[2- (methylsulfinyl) ethoxy]-N-[2-(diethylamino)ethyl] benzamide hydrochloride) (ML-1035) in male and female New Zealand white rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467455/),[l] / [kg],9.11,213541,DB01233,Metoclopramide
,1467455,Clearance,Clearance averaged 2.99 +/- 1.11 l h-1 kg-1 in males and 16.73 +/- 7.29 l h-1 kg-1 in females.,Sex-differences in the disposition of substituted benzamides: pharmacokinetics of a gastroprokinetic agent (4-amino-5-chloro-2-[2- (methylsulfinyl) ethoxy]-N-[2-(diethylamino)ethyl] benzamide hydrochloride) (ML-1035) in male and female New Zealand white rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467455/),[l] / [h·kg],2.99,213542,DB01233,Metoclopramide
,1467455,Clearance,Clearance averaged 2.99 +/- 1.11 l h-1 kg-1 in males and 16.73 +/- 7.29 l h-1 kg-1 in females.,Sex-differences in the disposition of substituted benzamides: pharmacokinetics of a gastroprokinetic agent (4-amino-5-chloro-2-[2- (methylsulfinyl) ethoxy]-N-[2-(diethylamino)ethyl] benzamide hydrochloride) (ML-1035) in male and female New Zealand white rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467455/),[l] / [h·kg],16.73,213543,DB01233,Metoclopramide
,1467455,Absolute bioavailability,"Absolute bioavailability after oral administration was 7.35 per cent for males and 12.31 per cent for females, suggesting that ML-1035 undergoes significant first-pass elimination.",Sex-differences in the disposition of substituted benzamides: pharmacokinetics of a gastroprokinetic agent (4-amino-5-chloro-2-[2- (methylsulfinyl) ethoxy]-N-[2-(diethylamino)ethyl] benzamide hydrochloride) (ML-1035) in male and female New Zealand white rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467455/),%,7.35,213544,DB01233,Metoclopramide
,1467455,Absolute bioavailability,"Absolute bioavailability after oral administration was 7.35 per cent for males and 12.31 per cent for females, suggesting that ML-1035 undergoes significant first-pass elimination.",Sex-differences in the disposition of substituted benzamides: pharmacokinetics of a gastroprokinetic agent (4-amino-5-chloro-2-[2- (methylsulfinyl) ethoxy]-N-[2-(diethylamino)ethyl] benzamide hydrochloride) (ML-1035) in male and female New Zealand white rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467455/),%,12.31,213545,DB01233,Metoclopramide
,508553,elimination half-life postdistribution,The elimination half-life postdistribution was 4.9 h.,Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/508553/),h,4.9,214690,DB01233,Metoclopramide
,508553,"apparent volume of distribution, Vd","The apparent volume of distribution, Vd, was 3.0 1/kg body weight.",Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/508553/),[1] / [kg],3.0,214691,DB01233,Metoclopramide
,508553,bioavailability,The extent of bioavailability was the same following the two different formulations suggesting a first-pass elimination of 25-40%.,Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/508553/),,25-40,214692,DB01233,Metoclopramide
,6707886,bioavailability (F),"The bioavailability (F) values of I at dosage levels 0.1, 0.5, 1.0, and 5.0 mg/kg were 0.49, 0.75, 0.77, and 0.83, respectively.",Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707886/),,0.49,216866,DB01233,Metoclopramide
,6707886,bioavailability (F),"The bioavailability (F) values of I at dosage levels 0.1, 0.5, 1.0, and 5.0 mg/kg were 0.49, 0.75, 0.77, and 0.83, respectively.",Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707886/),,0.75,216867,DB01233,Metoclopramide
,6707886,bioavailability (F),"The bioavailability (F) values of I at dosage levels 0.1, 0.5, 1.0, and 5.0 mg/kg were 0.49, 0.75, 0.77, and 0.83, respectively.",Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707886/),,0.77,216868,DB01233,Metoclopramide
,6707886,bioavailability (F),"The bioavailability (F) values of I at dosage levels 0.1, 0.5, 1.0, and 5.0 mg/kg were 0.49, 0.75, 0.77, and 0.83, respectively.",Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707886/),,0.83,216869,DB01233,Metoclopramide
,28379057,bioavailability,"Compared to control IM, the bioavailability of oral tablets of MCP was 24.9%, while that of nasal spray was 62.3%.",Metoclopramide nasal spray in vitro evaluation and in vivo pharmacokinetic studies in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28379057/),%,24.9,218098,DB01233,Metoclopramide
,28379057,bioavailability,"Compared to control IM, the bioavailability of oral tablets of MCP was 24.9%, while that of nasal spray was 62.3%.",Metoclopramide nasal spray in vitro evaluation and in vivo pharmacokinetic studies in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28379057/),%,62.3,218099,DB01233,Metoclopramide
,2079650,steady-state concentrations,"Following the maternal infusions, metoclopramide reached average steady-state concentrations of 50.0 +/- 20.2 ng/mL in the ewe and 27.1 +/- 8.6 ng/mL in the fetus, with a mean fetal-to-maternal concentration ratio of 0.57 +/- 0.14.",Fetal and maternal placental and nonplacental clearances of metoclopramide in chronically instrumented pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079650/),[ng] / [ml],50.0,218815,DB01233,Metoclopramide
,2079650,steady-state concentrations,"Following the maternal infusions, metoclopramide reached average steady-state concentrations of 50.0 +/- 20.2 ng/mL in the ewe and 27.1 +/- 8.6 ng/mL in the fetus, with a mean fetal-to-maternal concentration ratio of 0.57 +/- 0.14.",Fetal and maternal placental and nonplacental clearances of metoclopramide in chronically instrumented pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079650/),[ng] / [ml],27.1,218816,DB01233,Metoclopramide
,2079650,fetal-to-maternal concentration ratio,"Following the maternal infusions, metoclopramide reached average steady-state concentrations of 50.0 +/- 20.2 ng/mL in the ewe and 27.1 +/- 8.6 ng/mL in the fetus, with a mean fetal-to-maternal concentration ratio of 0.57 +/- 0.14.",Fetal and maternal placental and nonplacental clearances of metoclopramide in chronically instrumented pregnant sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079650/),,0.57,218817,DB01233,Metoclopramide
,2079650,steady-state concentrations,"Mean steady-state concentrations were 13.8 +/- 4.5 and 253.7 +/- 92.1 ng/mL in the ewe and fetus, respectively, after fetal drug administration.",Fetal and maternal placental and nonplacental clearances of metoclopramide in chronically instrumented pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079650/),[ng] / [ml],13.8,218818,DB01233,Metoclopramide
,2079650,steady-state concentrations,"Mean steady-state concentrations were 13.8 +/- 4.5 and 253.7 +/- 92.1 ng/mL in the ewe and fetus, respectively, after fetal drug administration.",Fetal and maternal placental and nonplacental clearances of metoclopramide in chronically instrumented pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079650/),[ng] / [ml],253.7,218819,DB01233,Metoclopramide
,2079650,Clearance,Clearance of metoclopramide across the placenta from the fetus to the ewe (6.2 +/- 2.4 L/h/kg) was significantly greater than that in the reverse direction (4.3 +/- 1.3 L/h/kg) and accounted for approximately 80% of total fetal drug elimination.,Fetal and maternal placental and nonplacental clearances of metoclopramide in chronically instrumented pregnant sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079650/),[l] / [h·kg],6.2,218820,DB01233,Metoclopramide
,2079650,Clearance,Clearance of metoclopramide across the placenta from the fetus to the ewe (6.2 +/- 2.4 L/h/kg) was significantly greater than that in the reverse direction (4.3 +/- 1.3 L/h/kg) and accounted for approximately 80% of total fetal drug elimination.,Fetal and maternal placental and nonplacental clearances of metoclopramide in chronically instrumented pregnant sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079650/),[l] / [h·kg],4.3,218821,DB01233,Metoclopramide
,10514351,constant current,"MCP, an antiemetic, low molecular weight, cationic drug intended for systemic delivery, was delivered from the anode of IP systems at a constant current of 100 microA/cm(2).",Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514351/),[μa] / [cm(2],100,223550,DB01233,Metoclopramide
,10514351,steady-state MCP flux,"In both groups, a steady-state MCP flux of about 100 microg/(cm(2) x h) was achieved after only 1 h of transport, and input rate dropped dramatically immediately after removal of the system.",Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514351/),[μg] / [cm(2)·h],100,223551,DB01233,Metoclopramide
,10514351,flux,"In vitro, HC flux through human epidermis from an MCP plus HC formulation was 2.8 +/- 1.1 microg/(cm(2) x h) after 4 h transport at 100 microA/cm(2), suggesting negligible systemic exposure to hydrocortisone.",Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514351/),[μg] / [cm(2)·h],2.8,223552,DB01233,Metoclopramide
,22328192,tmax,"Peak plasmatic concentrations were not statistically different with both formulations, but occurred significantly later (p < 0.05) with the modified-release form [tmax: 3.15 (1.28) vs. 0.85 (0.32) h and tmax-ss: 2.92 (1.19) vs. 1.04 (0.43) h].","Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22328192/),h,3.15,227008,DB01233,Metoclopramide
,22328192,tmax,"Peak plasmatic concentrations were not statistically different with both formulations, but occurred significantly later (p < 0.05) with the modified-release form [tmax: 3.15 (1.28) vs. 0.85 (0.32) h and tmax-ss: 2.92 (1.19) vs. 1.04 (0.43) h].","Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22328192/),h,0.85,227009,DB01233,Metoclopramide
,22328192,tmax-ss,"Peak plasmatic concentrations were not statistically different with both formulations, but occurred significantly later (p < 0.05) with the modified-release form [tmax: 3.15 (1.28) vs. 0.85 (0.32) h and tmax-ss: 2.92 (1.19) vs. 1.04 (0.43) h].","Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22328192/),h,2.92,227010,DB01233,Metoclopramide
,22328192,tmax-ss,"Peak plasmatic concentrations were not statistically different with both formulations, but occurred significantly later (p < 0.05) with the modified-release form [tmax: 3.15 (1.28) vs. 0.85 (0.32) h and tmax-ss: 2.92 (1.19) vs. 1.04 (0.43) h].","Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22328192/),h,1.04,227011,DB01233,Metoclopramide
,22328192,Cavgτ,"There was no difference noted in the average plasma concentrations [Cavgτ: 23.90 (7.90) vs. 20.64 (7.43) ng/mL after the first dose; and Cavg-ss: 31.14 (9.64) vs. 35.59 (12.29) ng/mL after the last dose, (p > 0.05)].","Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22328192/),[ng] / [ml],23.90,227012,DB01233,Metoclopramide
,22328192,Cavgτ,"There was no difference noted in the average plasma concentrations [Cavgτ: 23.90 (7.90) vs. 20.64 (7.43) ng/mL after the first dose; and Cavg-ss: 31.14 (9.64) vs. 35.59 (12.29) ng/mL after the last dose, (p > 0.05)].","Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22328192/),[ng] / [ml],20.64,227013,DB01233,Metoclopramide
,22328192,Cavg-ss,"There was no difference noted in the average plasma concentrations [Cavgτ: 23.90 (7.90) vs. 20.64 (7.43) ng/mL after the first dose; and Cavg-ss: 31.14 (9.64) vs. 35.59 (12.29) ng/mL after the last dose, (p > 0.05)].","Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy male subjects. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22328192/),[ng] / [ml],31.14,227014,DB01233,Metoclopramide
,22328192,Cavg-ss,"There was no difference noted in the average plasma concentrations [Cavgτ: 23.90 (7.90) vs. 20.64 (7.43) ng/mL after the first dose; and Cavg-ss: 31.14 (9.64) vs. 35.59 (12.29) ng/mL after the last dose, (p > 0.05)].","Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy male subjects. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22328192/),[ng] / [ml],35.59,227015,DB01233,Metoclopramide
,19958151,absolute bioavailability,"Finally, the bioavailability study in rabbits revealed that the absolute bioavailability of MET HCl was significantly increased from 40.67% in the case of the oral drug solution to 54.61% in the case of the nasal in situ gel.",In situ gels of Metoclopramide Hydrochloride for intranasal delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19958151/),%,40.67,228160,DB01233,Metoclopramide
,19958151,absolute bioavailability,"Finally, the bioavailability study in rabbits revealed that the absolute bioavailability of MET HCl was significantly increased from 40.67% in the case of the oral drug solution to 54.61% in the case of the nasal in situ gel.",In situ gels of Metoclopramide Hydrochloride for intranasal delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19958151/),%,54.61,228161,DB01233,Metoclopramide
,7141754,peak concentration,"The peak concentration of tolfenamic acid was 4.1 +/- 0.9 micrograms/ml (mean +/- s.e.m.), the time peak 1.9 +/- 0.2 h, and the elimination half-life 2.3 +/- 0.5 h calculated from the values without metoclopramide.",The effect of metoclopramide on the absorption of tolfenamic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7141754/),[μg] / [ml],4.1,229406,DB01233,Metoclopramide
,7141754,time peak,"The peak concentration of tolfenamic acid was 4.1 +/- 0.9 micrograms/ml (mean +/- s.e.m.), the time peak 1.9 +/- 0.2 h, and the elimination half-life 2.3 +/- 0.5 h calculated from the values without metoclopramide.",The effect of metoclopramide on the absorption of tolfenamic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7141754/),h,1.9,229407,DB01233,Metoclopramide
,7141754,elimination half-life,"The peak concentration of tolfenamic acid was 4.1 +/- 0.9 micrograms/ml (mean +/- s.e.m.), the time peak 1.9 +/- 0.2 h, and the elimination half-life 2.3 +/- 0.5 h calculated from the values without metoclopramide.",The effect of metoclopramide on the absorption of tolfenamic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7141754/),h,2.3,229408,DB01233,Metoclopramide
,7141754,peak concentration,The peak concentration of metoclopramide was 69 +/- 6.3 ng/ml and the time to peak 118 +/- 29 min.,The effect of metoclopramide on the absorption of tolfenamic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7141754/),[ng] / [ml],69,229409,DB01233,Metoclopramide
,7141754,time to peak,The peak concentration of metoclopramide was 69 +/- 6.3 ng/ml and the time to peak 118 +/- 29 min.,The effect of metoclopramide on the absorption of tolfenamic acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7141754/),min,118,229410,DB01233,Metoclopramide
,7199924,bioavailability,"The bioavailability results were as follows: metoclopramide of Gastronerton tablets 80.3%, metoclopramide of the tablets of the reference drug 57.6%, Gastronerton solution 76.7%, solution of the reference drug 49.7%.",[Bioavailability of metoclopramide with special reference to relevant literature data]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199924/),%,80.3,229499,DB01233,Metoclopramide
,7199924,bioavailability,"The bioavailability results were as follows: metoclopramide of Gastronerton tablets 80.3%, metoclopramide of the tablets of the reference drug 57.6%, Gastronerton solution 76.7%, solution of the reference drug 49.7%.",[Bioavailability of metoclopramide with special reference to relevant literature data]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199924/),%,57.6,229500,DB01233,Metoclopramide
,7199924,bioavailability,"The bioavailability results were as follows: metoclopramide of Gastronerton tablets 80.3%, metoclopramide of the tablets of the reference drug 57.6%, Gastronerton solution 76.7%, solution of the reference drug 49.7%.",[Bioavailability of metoclopramide with special reference to relevant literature data]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199924/),%,76.7,229501,DB01233,Metoclopramide
,7199924,bioavailability,"The bioavailability results were as follows: metoclopramide of Gastronerton tablets 80.3%, metoclopramide of the tablets of the reference drug 57.6%, Gastronerton solution 76.7%, solution of the reference drug 49.7%.",[Bioavailability of metoclopramide with special reference to relevant literature data]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199924/),%,49.7,229502,DB01233,Metoclopramide
,7199924,bioavailability,The bioavailability of metoclopramide of Gastronerton capsules was 54.8%.,[Bioavailability of metoclopramide with special reference to relevant literature data]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199924/),%,54.8,229503,DB01233,Metoclopramide
,7199924,half-life,The half-life values were between 2.8 and 8.3 h with a mean value of 5 h.,[Bioavailability of metoclopramide with special reference to relevant literature data]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199924/),h,2.8 and 8.3,229504,DB01233,Metoclopramide
,7199924,half-life,The half-life values were between 2.8 and 8.3 h with a mean value of 5 h.,[Bioavailability of metoclopramide with special reference to relevant literature data]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199924/),h,5,229505,DB01233,Metoclopramide
,3284095,concentration maximum (Cmax),"The average CsA concentration maximum (Cmax) was 528 ng/mL with an average time to maximum concentration (Tmax) of 4.7 hours, a mean residence time of 7.75 hours, with a Vdss/%F of 9.61 L/kg in the pancreas transplant recipients.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),[ng] / [ml],528,229880,DB01233,Metoclopramide
,3284095,time to maximum concentration (Tmax),"The average CsA concentration maximum (Cmax) was 528 ng/mL with an average time to maximum concentration (Tmax) of 4.7 hours, a mean residence time of 7.75 hours, with a Vdss/%F of 9.61 L/kg in the pancreas transplant recipients.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),h,4.7,229881,DB01233,Metoclopramide
,3284095,mean residence time,"The average CsA concentration maximum (Cmax) was 528 ng/mL with an average time to maximum concentration (Tmax) of 4.7 hours, a mean residence time of 7.75 hours, with a Vdss/%F of 9.61 L/kg in the pancreas transplant recipients.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),h,7.75,229882,DB01233,Metoclopramide
,3284095,Vdss/%F,"The average CsA concentration maximum (Cmax) was 528 ng/mL with an average time to maximum concentration (Tmax) of 4.7 hours, a mean residence time of 7.75 hours, with a Vdss/%F of 9.61 L/kg in the pancreas transplant recipients.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),[l] / [kg],9.61,229883,DB01233,Metoclopramide
,3284095,Cmax,"Additional studies of six patients receiving metoclopramide with CsA revealed an average Cmax of 723 ng/mL, an average Tmax of 2.3 hours, an average MRT of 6.08 hours, and an average Vdss/%F of 5.7% L/kg.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),[ng] / [ml],723,229884,DB01233,Metoclopramide
,3284095,Tmax,"Additional studies of six patients receiving metoclopramide with CsA revealed an average Cmax of 723 ng/mL, an average Tmax of 2.3 hours, an average MRT of 6.08 hours, and an average Vdss/%F of 5.7% L/kg.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),h,2.3,229885,DB01233,Metoclopramide
,3284095,MRT,"Additional studies of six patients receiving metoclopramide with CsA revealed an average Cmax of 723 ng/mL, an average Tmax of 2.3 hours, an average MRT of 6.08 hours, and an average Vdss/%F of 5.7% L/kg.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),h,6.08,229886,DB01233,Metoclopramide
,3284095,Vdss/%F,"Additional studies of six patients receiving metoclopramide with CsA revealed an average Cmax of 723 ng/mL, an average Tmax of 2.3 hours, an average MRT of 6.08 hours, and an average Vdss/%F of 5.7% L/kg.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),[%·l] / [kg],5.7,229887,DB01233,Metoclopramide
,3655009,elimination half-life,"The elimination half-life, steady-state volume of distribution, and total body clearance after the initial intravenous dose were 3.9 +/- 1.2 hr, 2.7 +/- 0.3 L/kg, and 0.57 +/- 0.14 L/hr/kg, respectively.",Bioavailability and disposition of metoclopramide after single- and multiple-dose administration in diabetic patients with gastroparesis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655009/),h,3.9,236366,DB01233,Metoclopramide
,3655009,steady-state volume of distribution,"The elimination half-life, steady-state volume of distribution, and total body clearance after the initial intravenous dose were 3.9 +/- 1.2 hr, 2.7 +/- 0.3 L/kg, and 0.57 +/- 0.14 L/hr/kg, respectively.",Bioavailability and disposition of metoclopramide after single- and multiple-dose administration in diabetic patients with gastroparesis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655009/),[l] / [kg],2.7,236367,DB01233,Metoclopramide
,3655009,total body clearance,"The elimination half-life, steady-state volume of distribution, and total body clearance after the initial intravenous dose were 3.9 +/- 1.2 hr, 2.7 +/- 0.3 L/kg, and 0.57 +/- 0.14 L/hr/kg, respectively.",Bioavailability and disposition of metoclopramide after single- and multiple-dose administration in diabetic patients with gastroparesis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655009/),[l] / [h·kg],0.57,236368,DB01233,Metoclopramide
,3655009,initial bioavailability,The initial bioavailability was 67.7 +/- 12.6%.,Bioavailability and disposition of metoclopramide after single- and multiple-dose administration in diabetic patients with gastroparesis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655009/),%,67.7,236369,DB01233,Metoclopramide
,3655009,total body clearance,"After three weeks of chronic therapy, no significant differences in total body clearance (0.72 +/- 0.42 L/hr/kg) or bioavailability (77.5 +/- 16.8%) were observed.",Bioavailability and disposition of metoclopramide after single- and multiple-dose administration in diabetic patients with gastroparesis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655009/),[l] / [h·kg],0.72,236370,DB01233,Metoclopramide
,3655009,bioavailability,"After three weeks of chronic therapy, no significant differences in total body clearance (0.72 +/- 0.42 L/hr/kg) or bioavailability (77.5 +/- 16.8%) were observed.",Bioavailability and disposition of metoclopramide after single- and multiple-dose administration in diabetic patients with gastroparesis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655009/),%,77.5,236371,DB01233,Metoclopramide
,7250177,terminal half-life,The mean terminal half-life was 13.9 h after intravenous and 14.8 h after oral administration.,The pharmacokinetics of single doses of metoclopramide in renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250177/),h,13.9,238156,DB01233,Metoclopramide
,7250177,terminal half-life,The mean terminal half-life was 13.9 h after intravenous and 14.8 h after oral administration.,The pharmacokinetics of single doses of metoclopramide in renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250177/),h,14.8,238157,DB01233,Metoclopramide
,7250177,Total body clearance,Total body clearance after i.v. dosing was 16.7 l/h.,The pharmacokinetics of single doses of metoclopramide in renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250177/),[l] / [h],16.7,238158,DB01233,Metoclopramide
,7250177,Oral bioavailability,Oral bioavailability was 71.8%.,The pharmacokinetics of single doses of metoclopramide in renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250177/),%,71.8,238159,DB01233,Metoclopramide
,1487562,maximum peak plasma concentration (Cmax),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),[μg] / [ml],14.0,253528,DB01233,Metoclopramide
,1487562,time to reach Cmax (tmax),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),h,1.5,253529,DB01233,Metoclopramide
,1487562,half-life (t1/2),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),h,1.24,253530,DB01233,Metoclopramide
,1487562,area under the concentration (AUC0-infinity),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),[h·μg] / [ml],47.3,253531,DB01233,Metoclopramide
,1487562,mean residence time after oral administration (MRTpo),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),h,2.9,253532,DB01233,Metoclopramide
,1487562,CLR,"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),[ml] / [min],219,253533,DB01233,Metoclopramide
,1487562,percent cumulative urinary excretion in 0-24 hours,"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),,68.1,253534,DB01233,Metoclopramide
,6499354,AUC-24,Metoclopramide reduced the mean AUC-24 for tablets from 12.26 +/- 2.70 to 9.38 +/- 3.78 ng X hr/ml (P less than 0.001) and the CUE-48 from 119.0 +/- 22.4 to 97.6 +/- 22.2 micrograms (P less than 0.01).,Effect of metoclopramide on digoxin absorption from tablets and capsules. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499354/),[h·ng] / [ml],12.26,259992,DB01233,Metoclopramide
,6499354,AUC-24,Metoclopramide reduced the mean AUC-24 for tablets from 12.26 +/- 2.70 to 9.38 +/- 3.78 ng X hr/ml (P less than 0.001) and the CUE-48 from 119.0 +/- 22.4 to 97.6 +/- 22.2 micrograms (P less than 0.01).,Effect of metoclopramide on digoxin absorption from tablets and capsules. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499354/),[h·ng] / [ml],9.38,259993,DB01233,Metoclopramide
,6499354,CUE-48,Metoclopramide reduced the mean AUC-24 for tablets from 12.26 +/- 2.70 to 9.38 +/- 3.78 ng X hr/ml (P less than 0.001) and the CUE-48 from 119.0 +/- 22.4 to 97.6 +/- 22.2 micrograms (P less than 0.01).,Effect of metoclopramide on digoxin absorption from tablets and capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499354/),μg,119.0,259994,DB01233,Metoclopramide
,6499354,CUE-48,Metoclopramide reduced the mean AUC-24 for tablets from 12.26 +/- 2.70 to 9.38 +/- 3.78 ng X hr/ml (P less than 0.001) and the CUE-48 from 119.0 +/- 22.4 to 97.6 +/- 22.2 micrograms (P less than 0.01).,Effect of metoclopramide on digoxin absorption from tablets and capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499354/),μg,97.6,259995,DB01233,Metoclopramide
,6499354,AUC-24,There were no significant differences in mean AUC-24 (12.94 +/- 3.16 and 13.45 +/- 2.33 ng X hr/ml) and mean CUE-48 (117.8 +/- 23.4 and 109.7 +/- 25.0 micrograms) when capsules alone were compared to capsules with metoclopramide.,Effect of metoclopramide on digoxin absorption from tablets and capsules. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499354/),[h·ng] / [ml],12.94,259996,DB01233,Metoclopramide
,6499354,AUC-24,There were no significant differences in mean AUC-24 (12.94 +/- 3.16 and 13.45 +/- 2.33 ng X hr/ml) and mean CUE-48 (117.8 +/- 23.4 and 109.7 +/- 25.0 micrograms) when capsules alone were compared to capsules with metoclopramide.,Effect of metoclopramide on digoxin absorption from tablets and capsules. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499354/),[h·ng] / [ml],13.45,259997,DB01233,Metoclopramide
,6499354,CUE-48,There were no significant differences in mean AUC-24 (12.94 +/- 3.16 and 13.45 +/- 2.33 ng X hr/ml) and mean CUE-48 (117.8 +/- 23.4 and 109.7 +/- 25.0 micrograms) when capsules alone were compared to capsules with metoclopramide.,Effect of metoclopramide on digoxin absorption from tablets and capsules. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499354/),μg,117.8,259998,DB01233,Metoclopramide
,6499354,CUE-48,There were no significant differences in mean AUC-24 (12.94 +/- 3.16 and 13.45 +/- 2.33 ng X hr/ml) and mean CUE-48 (117.8 +/- 23.4 and 109.7 +/- 25.0 micrograms) when capsules alone were compared to capsules with metoclopramide.,Effect of metoclopramide on digoxin absorption from tablets and capsules. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499354/),μg,109.7,259999,DB01233,Metoclopramide
,7721226,apparent volume of distribution,Mefloquine has a large apparent volume of distribution of 200 L and is highly bound (98%) to plasma proteins.,Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721226/),l,200,260923,DB01233,Metoclopramide
,7721226,terminal half-life,The elimination is slow; the terminal half-life is 13 10 to 14 days in Thai patients with falciparum malaria.,Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721226/),d,13 10 to 14,260924,DB01233,Metoclopramide
,3349725,CL,"The typical pharmacokinetic parameters for an average individual (70kg, alkaline phosphatase = 100 IU/L) were: CL = 20 L/h; volume of distribution at steady state (Vdss) = 190L; terminal half-life = 8h.",Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349725/),[l] / [h],20,268361,DB01233,Metoclopramide
,3349725,volume of distribution at steady state (Vdss),"The typical pharmacokinetic parameters for an average individual (70kg, alkaline phosphatase = 100 IU/L) were: CL = 20 L/h; volume of distribution at steady state (Vdss) = 190L; terminal half-life = 8h.",Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349725/),l,190,268362,DB01233,Metoclopramide
,3349725,terminal half-life,"The typical pharmacokinetic parameters for an average individual (70kg, alkaline phosphatase = 100 IU/L) were: CL = 20 L/h; volume of distribution at steady state (Vdss) = 190L; terminal half-life = 8h.",Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349725/),h,8,268363,DB01233,Metoclopramide
,6683523,bioavailabilities,"Comparing the present results to literature data following i.v. administration of the drug, bioavailabilities between 54-75% could be calculated.",[Pharmacokinetics and bioequivalence of various oral formulations of metoclopramide]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683523/),%,54-75,269104,DB01233,Metoclopramide
,6683523,terminal elimination half-lives,"The initial distribution of the drug following administration of tablets and drops is very rapid, the terminal elimination half-lives ranges from 4.1-5.7 h and the apparent volumes of distribution were found to be 5.2-5.8 l/kg body weight.",[Pharmacokinetics and bioequivalence of various oral formulations of metoclopramide]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683523/),h,4.1-5.7,269105,DB01233,Metoclopramide
,6683523,apparent volumes of distribution,"The initial distribution of the drug following administration of tablets and drops is very rapid, the terminal elimination half-lives ranges from 4.1-5.7 h and the apparent volumes of distribution were found to be 5.2-5.8 l/kg body weight.",[Pharmacokinetics and bioequivalence of various oral formulations of metoclopramide]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683523/),[l] / [body·kg·weight],5.2-5.8,269106,DB01233,Metoclopramide
,15849845,t(+15),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,5.4,269747,DB01233,Metoclopramide
,15849845,t(+15),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,3.3,269748,DB01233,Metoclopramide
,15849845,t(+30),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,6.7,269749,DB01233,Metoclopramide
,15849845,t(+30),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,3.7,269750,DB01233,Metoclopramide
,15849845,t(+60),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,7.7,269751,DB01233,Metoclopramide
,15849845,t(+60),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,5.1,269752,DB01233,Metoclopramide
,15849845,t(+120),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,8.5,269753,DB01233,Metoclopramide
,15849845,t(+120),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,5.2,269754,DB01233,Metoclopramide
,15849845,AUC,The AUC value was 34% larger in the metoclopramide group vs control group (574-/+296 vs 429-/+309; P=0.027).,Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,574,269755,DB01233,Metoclopramide
,15849845,AUC,The AUC value was 34% larger in the metoclopramide group vs control group (574-/+296 vs 429-/+309; P=0.027).,Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,429,269756,DB01233,Metoclopramide
,582108,half-life,Following a very short distributive phase an elimination phase is observed with a half-life of 3--6 h over the period studied.,[Preliminary pharmacokinetics of metoclopramide in humans. Plasma levels following a single oral and intravenous dose (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582108/),h,3--6,270186,DB01233,Metoclopramide
,6360466,oral bioavailability,"Metoclopramide is rapidly and well absorbed from the gastrointestinal tract, and in man undergoes variable first-pass metabolism (oral bioavailability 32 to 100%).",Clinical pharmacokinetics of metoclopramide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6360466/),%,32 to 100,271794,DB01233,Metoclopramide
